var title_f14_59_15280="Methotrexate-induced pneumonitis in RA";
var content_f14_59_15280=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F58722&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F58722&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Methotrexate-induced pneumonitis in rheumatoid arthritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 345px; height: 384px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chest x-ray from a patient with acute methotrexate pneumonitis demonstrating bilateral diffuse parenchymal opacities.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Fiona R Lake, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_59_15280=[""].join("\n");
var outline_f14_59_15280=null;
var title_f14_59_15281="Pathologic staging prostate CA";
var content_f14_59_15281=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F80052&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F80052&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 530px\">",
"   <div class=\"ttl\">",
"    Pathological staging of prostate cancer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 510px; height: 342px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Radical prostatectomy allows the determination of the extent of cancer in the prostate gland, prostate capsule, seminal vesicle, and lymph nodes because these tissues are removed and examined under the microscope. The likelihood of remaining disease free at ten years following prostatectomy is related to the extent of capsular penetration, whether the cancer is specimen confined, and whether there is evidence of positive margins.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted with permission from Garnick, M, Patient's Guide to Prostate Cancer, Penguin, New York, 1999, p. 45.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_59_15281=[""].join("\n");
var outline_f14_59_15281=null;
var title_f14_59_15282="Cervical dermatomes 2";
var content_f14_59_15282=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F79158&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F79158&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 562px\">",
"   <div class=\"ttl\">",
"    Cervical dermatomes",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 542px; height: 552px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_59_15282=[""].join("\n");
var outline_f14_59_15282=null;
var title_f14_59_15283="Tripe palm";
var content_f14_59_15283=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F61955&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F61955&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Tripe palm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 266px; height: 387px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The palmar ridges show maximal accentuation, thus resembling the mucosa of the stomach of a ruminant (tripe palm).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Fitzpatrick, TB, Johnson, RA, Wolff, K, Suurmond, D. Color Atlas of Clinical Dermatology: Common and Serious Diseases. McGraw Hill, New York 2001. p.151. Copyright &copy; 2001 McGraw Hill Companies, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_59_15283=[""].join("\n");
var outline_f14_59_15283=null;
var title_f14_59_15284="Tincture of opium: Patient drug information";
var content_f14_59_15284=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Tincture of opium: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/3/35893?source=see_link\">",
"     see \"Tincture of opium: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?15/62/16357?source=see_link\">",
"     see \"Tincture of opium: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10013559\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691815",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat loose stools (diarrhea).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10013558\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702637",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to opium tincture or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10013563\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697693",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may be habit-forming with long-term use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before you use other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10013564\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10013566\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699000",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Poor pain control.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699014",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very hard stools (constipation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10013561\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10013562\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10013567\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10013568\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11815 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-122.96.59.103-ECAAE0F0B7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_59_15284=[""].join("\n");
var outline_f14_59_15284=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013559\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013558\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013563\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013564\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013566\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013561\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013562\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013567\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013568\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?35/3/35893?source=related_link\">",
"      Tincture of opium: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?15/62/16357?source=related_link\">",
"      Tincture of opium: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_59_15285="Third degree (complete) atrioventricular block";
var content_f14_59_15285=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Third degree (complete) atrioventricular block",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/59/15285/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/59/15285/contributors\">",
"     William H Sauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/59/15285/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/59/15285/contributors\">",
"     Leonard I Ganz, MD, FHRS, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/59/15285/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/59/15285/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/59/15285/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 5, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrioventricular (AV) block is defined as a delay or interruption in the transmission of an impulse from the atria to the ventricles due to an anatomical or functional impairment in the conduction system. The conduction disturbance can be transient or permanent. The conduction can be delayed, intermittent, or absent. The commonly used terminology includes first degree (slowed conduction without missed beats), second degree (missed beats, often in a regular pattern, eg, 2:1, 3:2, or higher degrees of block), and third degree or complete AV block. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/21/17749?source=see_link\">",
"     \"ECG tutorial: Atrioventricular block\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical manifestations and management of third degree AV block will be discussed here. Congenital complete heart block, the etiology of AV block in general, and the management of other specific types of AV block are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/16/32007?source=see_link\">",
"     \"Etiology of atrioventricular block\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/8/10376?source=see_link\">",
"     \"Congenital third degree (complete) atrioventricular block\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/38/41574?source=see_link\">",
"     \"First degree atrioventricular block\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/42/18087?source=see_link\">",
"     \"Second degree atrioventricular block: Mobitz type I (Wenckebach block)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/62/998?source=see_link\">",
"     \"Second degree atrioventricular block: Mobitz type II\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     THIRD DEGREE AV BLOCK",
"    </span>",
"    &nbsp;&mdash;&nbsp;No atrial impulses reach the ventricle in third degree or complete heart block (",
"    <a class=\"graphic graphic_waveform graphicRef72863 \" href=\"UTD.htm?20/42/21160\">",
"     waveform 1",
"    </a>",
"    ). The block can exist in the AV node or in the infranodal specialized conduction system [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15285/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. A His-bundle electrocardiographic study can determine the site of block quite accurately, but the escape rhythm provides important clues.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Escape rhythms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Escape rhythms occur when a pacemaker other than the sinus node has sufficient time to depolarize, attain threshold, and produce a depolarization. In complete heart block, the escape rhythm that controls the ventricles can occur at any level below that of the conduction block and the morphology of the QRS complex can help to determine the location at which this is occurring.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If third degree AV block occurs within the AV node, about two-thirds of the escape rhythms have a narrow QRS complex, ie, a junctional or AV nodal rhythm (",
"      <a class=\"graphic graphic_waveform graphicRef65545 \" href=\"UTD.htm?12/50/13095\">",
"       waveform 2",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?14/59/15285/abstract/4-6\">",
"       4-6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Block at the level of the bundle of His is also typically associated with a narrow QRS complex.",
"     </li>",
"     <li>",
"      Patients with trifascicular block have a subjunctional escape rhythm with a wide QRS complex (",
"      <a class=\"graphic graphic_waveform graphicRef51446 \" href=\"UTD.htm?28/52/29509\">",
"       waveform 3",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If the escape rhythm has a normal QRS duration of less than 120 msec, the block occurs with almost equal frequency in the AV node and the bundle of His [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15285/abstract/4\">",
"     4",
"    </a>",
"    ]. In comparison, involvement of these sites is infrequent with a prolonged QRS; the block in this setting is in the fascicles or bundle branches in over 80 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15285/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Rate and response to interventions",
"    </span>",
"    &nbsp;&mdash;&nbsp;As a general rule, the more distal the block, the slower will be the escape pacemaker. Low pacemakers have a rate of 40 beats per minute or less and often are unreliable, resulting in a very slow rate or asystole. Syncope is most common in this group.",
"   </p>",
"   <p>",
"    The effects of autonomic tone, exercise, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/23/11640?source=see_link\">",
"     atropine",
"    </a>",
"    may all be helpful in determining the site of block [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15285/abstract/5,7-12\">",
"     5,7-12",
"    </a>",
"    ]. High junctional pacemakers may respond with an increase in heart rate to exercise, catecholamines, or atropine, and a decrease in heart rate after vagal maneuvers. In comparison, lower pacemakers are less responsive to autonomic manipulation.",
"   </p>",
"   <p>",
"    In addition to affecting the heart rate, these interventions also may improve AV conduction. As an example,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/23/11640?source=see_link\">",
"     atropine",
"    </a>",
"    can partially or completely restore conduction when complete heart block induced by an acute inferior myocardial infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15285/abstract/10\">",
"     10",
"    </a>",
"    ]. In this setting, the block is presumed to reflect ischemia in the AV node, which is supplied by the right coronary artery in 90 percent of individuals. The conduction defect generally resolves in one or two weeks, since collaterals from the left coronary system protect against infarction of the AV node.",
"   </p>",
"   <p>",
"    A contrasting response may be seen in some patients in whom conduction can be completely or partially restored by increasing vagal tone by carotid sinus massage or the Valsalva maneuver. The presumed mechanism is slowing the rate of the sinus node, thereby allowing more time for the tissue in which the block occurs to recover its excitability.",
"   </p>",
"   <p>",
"    Increasing vagal tone can also slow or block AV nodal conduction. In some cases, this will reveal an accelerated idioventricular rhythm (60 to 100",
"    <span class=\"nowrap\">",
"     beat/min)",
"    </span>",
"    that may be a clue to underlying myocardial infarction or digitalis intoxication.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complete heart block accompanied by a slow pacemaker or asystole can result in a variety of potentially serious symptoms including dizziness, presyncope and syncope (Stokes-Adams attacks), ventricular tachycardia, and ventricular fibrillation (",
"    <a class=\"graphic graphic_waveform graphicRef72863 \" href=\"UTD.htm?20/42/21160\">",
"     waveform 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15285/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. The slow rate also can worsen the symptoms of heart failure and angina pectoris.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapy of complete heart block begins by looking for and correcting reversible causes such as myocardial ischemia, increased vagal tone, and drugs that depress conduction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/16/32007?source=see_link\">",
"     \"Etiology of atrioventricular block\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If no reversible causes are present, treatment of AV block involves the avoidance of medications that impair AV conduction (when possible), and permanent pacemaker placement in most patients. Detailed reviews of the indications for permanent pacemaker placement and of the modes of cardiac pacing are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/52/27463?source=see_link&amp;anchor=H10#H10\">",
"     \"Indications for permanent cardiac pacing\", section on 'Acquired AV block'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/51/1849?source=see_link\">",
"     \"Modes of cardiac pacing: Nomenclature and selection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the emergent setting,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/23/11640?source=see_link\">",
"     atropine",
"    </a>",
"    may also be effective by reversing the decrease in AV nodal conduction induced by vagal tone. A favorable response to atropine also suggests that AV block is due to abnormal conduction in the AV node, since the more distal conducting system is not as sensitive to vagal activity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Electrophysiology study",
"    </span>",
"    &nbsp;&mdash;&nbsp;With a few selected exceptions, electrophysiologic studies are not necessary in patients with complete AV block [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15285/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Pacemaker indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;We agree with the 2008 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart",
"    <span class=\"nowrap\">",
"     Association/Heart",
"    </span>",
"    Rhythm Society",
"    <span class=\"nowrap\">",
"     (ACC/AHA/HRS)",
"    </span>",
"    device guidelines recommendations for placement of permanent pacemakers in patients with complete atrioventricular block [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15285/abstract/16\">",
"     16",
"    </a>",
"    ]. Most patients with complete heart block have an indication for pacemaker placement. All patients with associated symptoms, ventricular pauses &ge;3 seconds, or a resting heart rate &lt;40",
"    <span class=\"nowrap\">",
"     beats/min",
"    </span>",
"    while awake have a class I indication. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/52/27463?source=see_link&amp;anchor=H5#H5\">",
"     \"Indications for permanent cardiac pacing\", section on 'Common indications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Neuromuscular diseases",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of neuromuscular diseases are associated with AV block. These include myotonic muscular dystrophy, Kearns-Sayre syndrome, Erb's dystrophy (limb-girdle), and peroneal muscular atrophy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/20/1351?source=see_link\">",
"     \"Inherited syndromes associated with cardiac disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These patients represent a special class and are treated more aggressively with pacemakers due to the potential for unpredictably rapid progression of conduction disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/52/27463?source=see_link&amp;anchor=H23#H23\">",
"     \"Indications for permanent cardiac pacing\", section on 'Neuromuscular diseases'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Pacing mode",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most important choice in most patients with complete AV block is whether to place a single or dual chamber pacemaker. Single chamber, VVI pacing was most commonly used in the past, and is still used in the emergent setting for temporary pacing. Single chamber pacemakers are easier to implant and less expensive. The major disadvantage of VVI pacing is that the normal synchrony between atrial and ventricular contraction is lost, which is hemodynamically unfavorable. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/51/1849?source=see_link&amp;anchor=H25#H25\">",
"     \"Modes of cardiac pacing: Nomenclature and selection\", section on 'Physiologic pacing'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In order to maintain physiologic pacing, dual chamber pacing is recommended. The advantages of physiologic pacing may be less significant in very elderly patients with AV block. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/51/1849?source=see_link&amp;anchor=H27#H27\">",
"     \"Modes of cardiac pacing: Nomenclature and selection\", section on 'Effect on morbidity and mortality'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?8/46/8931?source=see_link\">",
"       \"Patient information: Bradycardia (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?43/26/44449?source=see_link\">",
"       \"Patient information: Heart block in adults (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6034680\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      No atrial impulses reach the ventricle in third degree, or complete, heart block, which can exist in the AV node or in the infranodal specialized conduction system. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Third degree AV block'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In complete heart block, the escape rhythm can occur at any level below that of the conduction block, and the morphology of the QRS complex can help to determine the location at which this is occurring. If third degree AV block occurs within the AV node of the bundle of His, the escape rhythm tends to have a narrow QRS complex, whereas AV block occurring below the bundle of His (trifascicular block) results in a subjunctional escape rhythm with a wide QRS complex. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Escape rhythms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Complete heart block accompanied by a slow pacemaker or asystole can result in a variety of potentially serious symptoms including dizziness, presyncope and syncope (Stokes-Adams attacks), ventricular tachycardia, and ventricular fibrillation. The slow rate also can worsen the symptoms of heart failure and angina pectoris. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Therapy of complete heart block begins by looking for and correcting reversible causes such as myocardial ischemia, increased vagal tone, and drugs that depress AV conduction. If no reversible causes are present, treatment involves permanent pacemaker placement in most patients. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H732848594\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The author and UpToDate would like to thank Dr. Brian Olshansky, who contributed to earlier versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15285/abstract/1\">",
"      Narula OS, Javier RP, Samet P, Maramba LC. Significance of His and left bundle recordings from the left heart in man. Circulation 1970; 42:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15285/abstract/2\">",
"      Narula OS, Scherlag BJ, Javier RP, et al. Analysis of the A-V conduction defect in complete heart block utilizing His bundle electrograms. Circulation 1970; 41:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15285/abstract/3\">",
"      Guimond C, Puech P. Intra-His bundle blocks (102 cases). Eur J Cardiol 1976; 4:481.",
"     </a>",
"    </li>",
"    <li>",
"     Peuch P, Grolleau R, Guimond C. Incidence of different types of A-V block and their localization by His bundle recordings. In: The Conduction System of the Heart, Wellens HJJ, Lie KI, Janse MJ (Eds), Stenfert Kroese, Leiden 1976. p.467.",
"    </li>",
"    <li>",
"     Narula OS. Current concepts of atrioventricular block. In: His Bundle Electrocardiography and Clinical Electrophysiology, Narula OS (Ed), Davis, Philadelphia 1975. p.139.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15285/abstract/6\">",
"      Rosen KM, Dhingra RC, Loeb HS, Rahimtoola SH. Chronic heart block in adults. Clinical and electrophysiological observations. Arch Intern Med 1973; 131:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15285/abstract/7\">",
"      Schweitzer P, Mark H. The effect of atropine on cardiac arrhythmias and conduction. Part 1. Am Heart J 1980; 100:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15285/abstract/8\">",
"      Schweitzer P, Mark H. The effect of atropine on cardiac arrhythmias and conduction. Part 2. Am Heart J 1980; 100:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15285/abstract/9\">",
"      Narula OS, Scherlag BJ, Samet P, Javier RP. Atrioventricular block. Localization and classification by His bundle recordings. Am J Med 1971; 50:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15285/abstract/10\">",
"      Lie KI, Wellens HJ, Schuilenburg RM, Durrer D. Mechanism and significance of widened QRS complexes during complete atrioventricular block in acute inferior myocardial infarction. Am J Cardiol 1974; 33:833.",
"     </a>",
"    </li>",
"    <li>",
"     B&auml;r, FW, Den Dulk, K, Wellens, HJJ. Atrioventricular dissociation. In: Comprehensive Electrocardiology: Theory and Practice in Health and Disease, MacFarlane, PW, Lawrie, TDV (Eds), Pergamon Press, New York, 1989, p. 933.",
"    </li>",
"    <li>",
"     Josephson, ME. Clinical Cardiac Electrophysiology: Techniques and Interpretations. 2nd ed., Lea &amp; Febiger, Philadelphia, 1993.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15285/abstract/13\">",
"      Wellens HJ, Brugada P, B&auml;r FW. The role of intraventricular conduction disorders in precipitating sudden death. Ann N Y Acad Sci 1982; 382:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15285/abstract/14\">",
"      Ezri M, Lerman BB, Marchlinski FE, et al. Electrophysiologic evaluation of syncope in patients with bifascicular block. Am Heart J 1983; 106:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15285/abstract/15\">",
"      Zipes DP, DiMarco JP, Gillette PC, et al. Guidelines for clinical intracardiac electrophysiological and catheter ablation procedures. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Clinical Intracardiac Electrophysiologic and Catheter Ablation Procedures), developed in collaboration with the North American Society of Pacing and Electrophysiology. J Am Coll Cardiol 1995; 26:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15285/abstract/16\">",
"      Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. Circulation 2008; 117:e350.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 911 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-221.10.40.236-33BC93883C-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_59_15285=[""].join("\n");
var outline_f14_59_15285=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H6034680\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      THIRD DEGREE AV BLOCK",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Escape rhythms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Rate and response to interventions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Electrophysiology study",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Pacemaker indications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Neuromuscular diseases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Pacing mode",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6034680\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H732848594\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/911\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/911|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?20/42/21160\" title=\"waveform 1\">",
"      ECG third degree or complete AV block",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?12/50/13095\" title=\"waveform 2\">",
"      Third degree or complete AV block with narrow QRS escape",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?28/52/29509\" title=\"waveform 3\">",
"      Third degree or complete AV block with wide QRS escape",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/8/10376?source=related_link\">",
"      Congenital third degree (complete) atrioventricular block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/21/17749?source=related_link\">",
"      ECG tutorial: Atrioventricular block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/16/32007?source=related_link\">",
"      Etiology of atrioventricular block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/38/41574?source=related_link\">",
"      First degree atrioventricular block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/52/27463?source=related_link\">",
"      Indications for permanent cardiac pacing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/20/1351?source=related_link\">",
"      Inherited syndromes associated with cardiac disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/51/1849?source=related_link\">",
"      Modes of cardiac pacing: Nomenclature and selection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?8/46/8931?source=related_link\">",
"      Patient information: Bradycardia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?43/26/44449?source=related_link\">",
"      Patient information: Heart block in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/42/18087?source=related_link\">",
"      Second degree atrioventricular block: Mobitz type I (Wenckebach block)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/62/998?source=related_link\">",
"      Second degree atrioventricular block: Mobitz type II",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_59_15286="Sleep related breathing disorders in adults: Definitions";
var content_f14_59_15286=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Sleep related breathing disorders in adults: Definitions",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/59/15286/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/59/15286/contributors\">",
"     Kingman P Strohl, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/59/15286/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/59/15286/contributors\">",
"     Ruth Benca, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/59/15286/contributors\">",
"     Robert C Basner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/59/15286/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/59/15286/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/59/15286/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 29, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sleep related breathing disorders (formerly called sleep disordered breathing) refer to an abnormal respiratory pattern (eg, apneas, hypopneas, or respiratory effort related arousals) or an abnormal reduction in gas exchange (eg, hypoventilation) during sleep. They tend to repetitively alter sleep duration and architecture, resulting in daytime symptoms, signs, or organ system dysfunction. Sleep related breathing disorders are best characterized by polysomnography that has captured one or more periods of rapid eye movement (REM) sleep, as severe perturbations can be common during REM sleep [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15286/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will define the terms used to describe and characterize sleep related breathing disorders. The diagnosis and treatment of sleep related breathing disorders are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41607?source=see_link\">",
"     \"Clinical presentation and diagnosis of obstructive sleep apnea in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/48/2826?source=see_link\">",
"     \"Management of obstructive sleep apnea in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/43/8888?source=see_link\">",
"     \"Cheyne-Stokes breathing and obstructive sleep apnea in heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EVENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Breathing abnormalities that occur during sleep include apnea, hypopnea, respiratory effort related arousals, hypoventilation, and Cheyne-Stokes breathing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Apnea",
"    </span>",
"    &nbsp;&mdash;&nbsp;Apnea is the cessation, or near cessation, of airflow. It exists when airflow is less than 10 percent of pre-event baseline for at least 10 seconds in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15286/abstract/3\">",
"     3",
"    </a>",
"    ]. In children, the duration criteria are shorter. Apnea can be associated with arousals from sleep, increased arterial carbon dioxide, and decreased oxygen levels. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/38/44649?source=see_link\">",
"     \"Evaluation of suspected obstructive sleep apnea in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Apnea is most commonly detected using sensors placed at the nose and mouth of the sleeping patient. Inspiratory airflow (or its surrogate, nasal pressure) is typically used to identify an apnea, although both inspiratory and expiratory airflow are usually abnormal. In the absence of a good airflow signal, chest wall and abdominal expansion can be used as a surrogate measure. Apnea during sleep can be categorized as three types: obstructive apnea, central apnea, or mixed apnea.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Obstructive apnea",
"    </span>",
"    &nbsp;&mdash;&nbsp;An obstructive apnea occurs when airflow is absent or nearly absent, but ventilatory effort persists. It is caused by complete, or near complete, upper airway obstruction. Previously used terms include upper airway apnea and peripheral apnea (",
"    <a class=\"graphic graphic_figure graphicRef67032 \" href=\"UTD.htm?32/10/32941\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Central apnea",
"    </span>",
"    &nbsp;&mdash;&nbsp;A central apnea occurs when both airflow and ventilatory effort are absent (",
"    <a class=\"graphic graphic_figure graphicRef67031 \" href=\"UTD.htm?17/7/17533\">",
"     figure 2",
"    </a>",
"    ). Breathing cessation is proven by an absence of diaphragmatic activation, measured by electromyography (EMG) and esophageal manometry, although, in practice breathing effort is usually determined by respiratory inductance plethysmography.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Mixed apnea",
"    </span>",
"    &nbsp;&mdash;&nbsp;For a mixed apnea, there is an interval during which there is no respiratory effort (ie, central apnea pattern) followed by an interval during which there are obstructed respiratory efforts (",
"    <a class=\"graphic graphic_figure graphicRef75904 \" href=\"UTD.htm?31/28/32205\">",
"     figure 3",
"    </a>",
"    ). .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Hypopnea",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypopnea is a reduction of airflow to a degree that is insufficient to meet the criteria for an apnea. A precise definition has varied over time, according to technology, expert opinion, and reimbursement guidelines. The most recent definition, endorsed by the American Academy of Sleep Medicine (AASM), recommends that hypopnea be scored when all of the following three criteria are met [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15286/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Airflow decreases at least 30 percent from pre-event baseline",
"     </li>",
"     <li>",
"      The diminished airflow lasts at least 10 seconds",
"     </li>",
"     <li>",
"      The decreased airflow is accompanied by at least 3 percent oxyhemoglobin desaturation from pre-event baseline, or an arousal",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Of note, previous definitions endorsed by the AASM and still used by the Centers for Medicare and Medicaid Services use a 4 percent cutoff for oxyhemoglobin desaturation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15286/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Like apnea, hypopnea is detected using sensors or surrogate measures, such as chest wall expansion. Inspiratory airflow is typically used to identify a hypopnea, although both inspiratory and expiratory airflow are usually abnormal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2460895\">",
"    <span class=\"h3\">",
"     Obstructive hypopnea",
"    </span>",
"    &nbsp;&mdash;&nbsp;A hypopnea is considered obstructive if snoring occurs during the event, if there is increased inspiratory flattening of the nasal pressure waveform or airflow compared to baseline, or if there is associated thoracoabdominal paradox during the event but not during pre-event breathing [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15286/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2460915\">",
"    <span class=\"h3\">",
"     Central hypopnea",
"    </span>",
"    &nbsp;&mdash;&nbsp;A hyponea is considered central if none of the three criteria for obstructive hypopnea (snoring, increased inspiratory flattening of nasal pressure waveform, thoracoabdominal paradox) are met during the event [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15286/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Respiratory effort related arousals",
"    </span>",
"    &nbsp;&mdash;&nbsp;Respiratory effort related arousals (RERAs) exist when there is a sequence of breaths that lasts at least 10 seconds, characterized by increasing respiratory effort or flattening of the nasal pressure waveform followed by an arousal from sleep, which does not meet the criteria for an apnea or hypopnea [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15286/abstract/3\">",
"     3",
"    </a>",
"    ]. RERAs are often accompanied by a terminal snort or an abrupt change in respiratory measures.",
"   </p>",
"   <p>",
"    Daytime sleepiness, fatigue, or inattention can result from microarousals (ie, electroencephalographic activation lasting three seconds or less), despite the absence of apneas or hypopneas. Snoring may not be a prominent complaint. Symptoms are reduced by treatment that alleviates RERAs.",
"   </p>",
"   <p>",
"    RERAs (&gt;5 events per hour) associated with daytime sleepiness were previously called upper airway resistance syndrome (UARS), which was considered a subtype of obstructive sleep apnea (OSA). These patients have abnormal sleep and cardiorespiratory changes typically found in OSA. Patients previously diagnosed with UARS are now considered to have OSA. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Upper airways resistance syndrome'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Hypoventilation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypoventilation during sleep is defined as an increase in the arterial carbon dioxide (PaCO2) to a value &gt;55 mmHg for at least 10 minutes, or a &ge;10 mmHg rise in the PaC02 during sleep (compared with awake supine level) to a value exceeding 50 mmHg for at least 10 minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15286/abstract/3\">",
"     3",
"    </a>",
"    ]. Directly measuring the PaCO2 by arterial blood gas during a sleep study is optimal, but impractical. Transcutaneous CO2 measurements and expired end tidal CO2 are recommended alternatives. Sleep hypoventilation is often presumed, though not proven, when persistent oxyhemoglobin desaturation is detected without an alternative explanation, such as apnea or hypopnea.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H87773166\">",
"    <span class=\"h2\">",
"     Cheynes-Stokes breathing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Respiratory events in sleep are defined as Cheyne-Stokes breathing if there are at least three consecutive central apneas",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    central hypopneas separated by crescendo-decrescendo breathing with a cycle length (time from the beginning of a central apnea or hypopnea to the beginning of the next apnea or hypopnea) of at least 40 seconds. In addition, there must be at least five apneas or hypopneas per hour associated with the crescendo-decrescendo breathing pattern [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15286/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      This definition does not require a clinical situation such as heart failure, stroke, or renal failure, and there is little agreement as to how many repetitive breathing events must be present to consider the patient as having a Cheyne-Stokes breathing pattern. The AASM recommends that the number or duration of Cheyne-Stoke breathing events be specified in the sleep study report.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SUMMARY MEASURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Summary measures define the frequency of respiratory disturbances during sleep.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Apnea index",
"    </span>",
"    &nbsp;&mdash;&nbsp;The apnea index (AI) is the total number of apneas per hour of sleep.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Apnea hypopnea index",
"    </span>",
"    &nbsp;&mdash;&nbsp;The apnea hypopnea index (AHI) is the total number of apneas and hypopneas per hour of sleep. The AHI is most commonly calculated per hour of total sleep. However, an AHI is occasionally calculated per hour of non-REM sleep, per hour of REM sleep, or per hour of sleep in a certain position to provide insight into the sleep stage dependency or sleep position dependency of the sleep related breathing disorder. The AHI is the primary metric used to report polysomnography results.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Respiratory disturbance index",
"    </span>",
"    &nbsp;&mdash;&nbsp;The respiratory disturbance index (RDI) is the total number of events (eg, apneas, hypopneas, and RERAs) per hour of sleep. The RDI is generally larger than the AHI, because the RDI includes the frequency of RERAs, while the AHI does not.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Desaturation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oxygen desaturation is a frequent consequence of apnea and hypopnea. Several measures are used to quantify the severity of desaturation and should be included in polysomnography reports [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15286/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Oxygen desaturation index (ODI). This is the number of times that the oxygen saturation falls by more than 3 percentage points per hour of sleep",
"     </li>",
"     <li>",
"      Minimum levels (ie, troughs) of oxygen saturation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other measures that may be found in polysomnography reports include the fraction of sleep time spent at each level of oxygen saturation (ie, the percent time below an oxygen saturation of 90 percent) and the mean oxygen saturation. The former quantifies the cumulative exposure to hypoxemia, while the latter may be inversely associated with risk for cardiovascular disease and glucose intolerance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Arousal index",
"    </span>",
"    &nbsp;&mdash;&nbsp;The arousal index (ArI) is the total number of arousals per hour of sleep. It is generally lower than the AHI or RDI because approximately 20 percent of apneas or hypopneas are not accompanied by arousals that are evident on polysomnography. However, the ArI can be greater than the AHI or RDI if arousals occur due to causes other than apneas or hypopneas. As examples, arousals can be caused by periodic limb movements, noise, and sleep state transitions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Limitations",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is important to recognize a limitation that is common to all of the indices described above; each will differ according to the diagnostic study performed. Specifically, indices determined by polysomnography define the number of events per hour of electroencephalographically documented sleep, while indices determined by cardiopulmonary monitoring define the number of events per hour of recording time, subjectively estimated sleep time, or time in bed. Each of these measures tends to overestimate the sleep time, thus underestimating the index. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/30/38374?source=see_link\">",
"     \"Polysomnography in obstructive sleep apnea in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/20/17734?source=see_link\">",
"     \"Portable monitoring in obstructive sleep apnea in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SYNDROMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The different syndromes of sleep related breathing disorders are defined using the events and summary measures described above.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Obstructive sleep apnea syndromes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obstructive sleep apnea syndromes encompass obstructive sleep apnea (OSA) in adults and OSA in children. OSA in adults is defined as either [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15286/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      More than 15 apneas, hypopneas, or RERAs per hour of sleep (ie, an AHI or RDI &gt;15",
"      <span class=\"nowrap\">",
"       events/hr)",
"      </span>",
"      in an asymptomatic patient, OR",
"     </li>",
"     <li>",
"      More than 5 apneas, hypopneas, or RERAs per hour of sleep (ie, an AHI or RDI &gt;5 events per hour) in a patient with symptoms (eg, sleepiness, fatigue and inattention) or signs of disturbed sleep (eg, snoring, restless sleep, and respiratory pauses). More than 75 percent of the apneas or hypopneas must have an obstructive pattern.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Upper airways resistance syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals previously diagnosed with upper airway resistance syndrome (UARS) are now classified as having OSA by the International Classification of Sleep Disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15286/abstract/4\">",
"     4",
"    </a>",
"    ]. UARS refers to RERAs accompanied by symptoms or signs of disturbed sleep.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Central sleep apnea syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Central sleep apnea syndrome (CSAS) can be idiopathic (eg, primary central sleep apnea [CSA]) or secondary. Examples of secondary CSAS include Cheyne-Stokes breathing pattern, CSA due to high altitude periodic breathing, CSA due to a medical condition, and CSA due to a drug or substance [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15286/abstract/4\">",
"     4",
"    </a>",
"    ]. More than 75 percent of events should be central to qualify for this syndrome category.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Primary central sleep apnea",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary CSA exists when symptoms or signs of disturbed sleep are accompanied by more than five central apneas plus hypopneas per hour of sleep, and normocarbia during wakefulness [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15286/abstract/1\">",
"     1",
"    </a>",
"    ]. The threshold frequency of events that warrants treatment beyond that required for the underlying disease is unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Cheyne-Stokes breathing pattern",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cheyne-Stokes breathing pattern refers to a cyclic pattern of crescendo-decrescendo tidal volumes and central apneas, hypopneas, or both, often but not exclusively associated with a medical illness such as heart failure, renal failure or stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15286/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/29/44502?source=see_link&amp;anchor=H4409791#H4409791\">",
"     \"Central sleep apnea: Risk factors, clinical presentation, and diagnosis\", section on 'Diagnostic criteria'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/43/8888?source=see_link\">",
"     \"Cheyne-Stokes breathing and obstructive sleep apnea in heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Hypoventilation syndromes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with a hypoventilation syndrome generally have mild hypercarbia (PaC02 &gt; 48 mmHg) or elevated serum bicarbonate levels (HC03 &gt; 38",
"    <span class=\"nowrap\">",
"     mEg/L)",
"    </span>",
"    when awake, which worsen during sleep. Two hypoventilation syndromes, congenital central hypoventilation syndrome (CCHS) and obesity hypoventilation syndrome (OHS), are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/63/22520?source=see_link\">",
"     \"Disorders of ventilatory control\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/48/38661?source=see_link\">",
"     \"Clinical manifestations and diagnosis of obesity hypoventilation syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/2/21541?source=see_link\">",
"     \"Pathogenesis of obesity hypoventilation syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/32/29192?source=see_link\">",
"     \"Treatment of the obesity hypoventilation syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/5/12375?source=see_link\">",
"     \"Noninvasive positive pressure therapy of the obesity hypoventilation syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?25/25/26003?source=see_link\">",
"       \"Patient information: Sleep apnea in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sleep related breathing disorders (formerly called sleep disordered breathing) refers to abnormal respiratory patterns or abnormal hypoventilation during sleep. Hypoxemia unrelated to either can also occur. Daytime symptoms or signs of disturbed sleep can result, with or without organ system dysfunction. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Apnea is the cessation, or near cessation, of airflow. It exists when airflow is less than 10 percent of baseline for at least 10 seconds in adults. These criteria may vary among sleep laboratories and in children. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Apnea'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hypopnea is a reduction of airflow insufficient to meet the criteria for an apnea. It exists when all of the following three criteria are met, according to the current definition: airflow decreases at least 30 percent from baseline, there is diminished airflow lasting at least 10 seconds, and decreased airflow is accompanied by at least 3 percent oxyhemoglobin desaturation. Alternative scoring criteria exist. Like apneas, hypopneas may be categorized as either obstructive or central. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Hypopnea'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Respiratory effort related arousals (RERAs) exist when there is a sequence of breaths that lasts at least 10 seconds, is characterized by increasing respiratory effort or flattening of the nasal pressure waveform, and leads to an arousal from sleep, but does not meet criteria of an apnea or hypopnea. The inspiratory airflow or tidal volume is maintained during these episodes, but requires increased respiratory effort. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Respiratory effort related arousals'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The Apnea&ndash;hypopnea index (AHI) is the total number of apneas and hypopneas per hour of sleep. The respiratory disturbance index (RDI) is the total number of events (eg, apneas, hypopneas, and RERAs) per hour of sleep. The oxygen desaturation index (ODI) is the number of times that the oxygen saturation falls by more than 3 or 4 percent per hour of sleep. The arousal index (ArI) is the total number of arousals per hour of sleep. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Summary measures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Obstructive sleep apnea (OSA) in adults is defined as either:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      More than 15 apneas, hypopneas, or RERAs per hour of sleep in an asymptomatic patient, OR",
"     </li>",
"     <li>",
"      More than five apneas, hypopneas, or RERAs per hour of sleep in a patient with symptoms (eg, sleepiness, fatigue, or inattention) or signs of disturbed sleep (eg, snoring, restless sleep, and respiratory pauses). More than 75 percent of the apneas or hypopneas must have an obstructive pattern. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Obstructive sleep apnea syndromes'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Central sleep apnea syndrome includes primary central sleep apnea (CSA), Cheyne-Stokes breathing pattern, high altitude periodic breathing, CSA due to a medical condition, and CSA due to a drug or substance. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Central sleep apnea syndrome'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Iber C, Ancoli-Israel S, Chesson AL, et al. The AASM Manual for the Scoring of Sleep and Associated Events, American Academy of Sleep Medicine, West Chester, IL 2007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15286/abstract/2\">",
"      Standards and indications for cardiopulmonary sleep studies in children. American Thoracic Society. Am J Respir Crit Care Med 1996; 153:866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15286/abstract/3\">",
"      Berry RB, Budhiraja R, Gottlieb DJ, et al. Rules for scoring respiratory events in sleep: update of the 2007 AASM Manual for the Scoring of Sleep and Associated Events. Deliberations of the Sleep Apnea Definitions Task Force of the American Academy of Sleep Medicine. J Clin Sleep Med 2012; 8:597.",
"     </a>",
"    </li>",
"    <li>",
"     The International Classification of Sleep Disorders, 2nd edition, Diagnostic and Coding Manual, 2nd ed, Hauri PJ (Ed), American Academy of Sleep Medicine, Westchester 2005.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7693 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-210.101.131.232-0D05C0E861-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_59_15286=[""].join("\n");
var outline_f14_59_15286=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EVENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Apnea",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Obstructive apnea",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Central apnea",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Mixed apnea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Hypopnea",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2460895\">",
"      - Obstructive hypopnea",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2460915\">",
"      - Central hypopnea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Respiratory effort related arousals",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Hypoventilation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H87773166\">",
"      Cheynes-Stokes breathing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SUMMARY MEASURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Apnea index",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Apnea hypopnea index",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Respiratory disturbance index",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Desaturation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Arousal index",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Limitations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SYNDROMES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Obstructive sleep apnea syndromes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Upper airways resistance syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Central sleep apnea syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Primary central sleep apnea",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Cheyne-Stokes breathing pattern",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Hypoventilation syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/7693\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/7693|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?32/10/32941\" title=\"figure 1\">",
"      Obstructive sleep apnea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/7/17533\" title=\"figure 2\">",
"      Central sleep apnea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/28/32205\" title=\"figure 3\">",
"      Mixed sleep apnea",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/29/44502?source=related_link\">",
"      Central sleep apnea: Risk factors, clinical presentation, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/43/8888?source=related_link\">",
"      Cheyne-Stokes breathing and obstructive sleep apnea in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/48/38661?source=related_link\">",
"      Clinical manifestations and diagnosis of obesity hypoventilation syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41607?source=related_link\">",
"      Clinical presentation and diagnosis of obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/63/22520?source=related_link\">",
"      Disorders of ventilatory control",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/38/44649?source=related_link\">",
"      Evaluation of suspected obstructive sleep apnea in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/48/2826?source=related_link\">",
"      Management of obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/5/12375?source=related_link\">",
"      Noninvasive positive pressure therapy of the obesity hypoventilation syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/2/21541?source=related_link\">",
"      Pathogenesis of obesity hypoventilation syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?25/25/26003?source=related_link\">",
"      Patient information: Sleep apnea in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/30/38374?source=related_link\">",
"      Polysomnography in obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/20/17734?source=related_link\">",
"      Portable monitoring in obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/32/29192?source=related_link\">",
"      Treatment of the obesity hypoventilation syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_59_15287="Microsporidia life cycle";
var content_f14_59_15287=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F78098&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F78098&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Microsporidia life cycle",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 441px; height: 694px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The infective form of microsporidia is the resistant spore and it can survive for a long time in the environment",
"    <strong>",
"     (1)",
"    </strong>",
"    . The spore extrudes its polar tubule and infects the host cell",
"    <strong>",
"     (2)",
"    </strong>",
"    . The spore injects the infective sporoplasm into the eukaryotic host cell through the polar tubule",
"    <strong>",
"     (3)",
"    </strong>",
"    . Inside the cell, the sporoplasm undergoes extensive multiplication either by merogony (binary fission) or schizogony (multiple fission)",
"    <strong>",
"     (4)",
"    </strong>",
"    . This development can occur either in direct contact with the host cell cytoplasm (eg, Enterocytozoon bieneusi) or inside a vacuole termed parasitophorous vacuole (eg, E. intestinalis). Either free in the cytoplasm or inside a parasitophorous vacuole, microsporidia develop by sporogony to mature spores",
"    <strong>",
"     (5)",
"    </strong>",
"    . During sporogony, a thick wall is formed around the spore, which provides resistance to adverse environmental conditions. When the spores increase in number and completely fill the host cell cytoplasm, the cell membrane is disrupted and releases the spores to the surroundings",
"    <strong>",
"     (6)",
"    </strong>",
"    . These free mature spores can infect new cells thus continuing the cycle.",
"    <div class=\"footnotes\">",
"     * Development inside parasitophorous vacuole also occurs in E. hellum and E. cuniculi.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Centers for Disease Control and Prevention. Parasites and Health: Microsporidiosis. Available at:",
"     <a href=\"file://dpd.cdc.gov/dpdx/HTML/Microsporidiosis.htm\" target=\"_blank\">",
"      file://dpd.cdc.gov/dpdx/HTML/Microsporidiosis.htm",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_59_15287=[""].join("\n");
var outline_f14_59_15287=null;
var title_f14_59_15288="Urinary tract complications of myelomeningocele (spina bifida)";
var content_f14_59_15288=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Urinary tract complications of myelomeningocele (spina bifida)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/59/15288/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/59/15288/contributors\">",
"     Laurence S Baskin, MD, FAAP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/59/15288/contributors\">",
"     Angelique Champeau, CPNP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/59/15288/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/59/15288/contributors\">",
"     Marc C Patterson, MD, FRACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/59/15288/contributors\">",
"     Leonard E Weisman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/59/15288/contributors\">",
"     Duncan Wilcox, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/59/15288/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/59/15288/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/59/15288/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 9, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nearly all patients with myelomeningocele have bladder dysfunction (neurogenic bladder). This may adversely affect urinary continence and quality of life, and can also lead to progressive deterioration of the upper urinary tract and chronic renal disease. Thirty to 40 percent of children with myelomeningocele develop some degree of renal dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15288/abstract/1\">",
"     1",
"    </a>",
"    ]. Treatment to reduce bladder pressures and minimize urine stasis often prevents or attenuates this complication.",
"   </p>",
"   <p>",
"    The assessment and management of the urinary tract complications of spina bifida are discussed here. Other aspects of myelomeningocele are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/62/33767?source=see_link\">",
"     \"Pathophysiology and clinical manifestations of myelomeningocele (spina bifida)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/46/26344?source=see_link\">",
"     \"Overview of the management of myelomeningocele (spina bifida)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with myelomeningocele have problems with storage",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    emptying of urine because the spinal cord lesion disrupts central nervous system control of urinary voiding mechanisms. The abnormalities of lower urinary tract dynamics include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Flaccid bladder",
"     </li>",
"     <li>",
"      High pressure bladder",
"     </li>",
"     <li>",
"      Hyperreflexic bladder",
"     </li>",
"     <li>",
"      Open bladder neck,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      overactive",
"      <span class=\"nowrap\">",
"       external/internal",
"      </span>",
"      sphincter",
"     </li>",
"     <li>",
"      Lack of coordination between the bladder and the external sphincter during voiding",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      bladder filling (detrusor sphincter dyssynergia)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Neither the location of the spinal lesion, nor the neurologic examination are sufficient to predict the type or severity of urinary tract dysfunction, because the spinal cord level at which the bladder is controlled is below the spinal roots directing lower extremity function (",
"    <a class=\"graphic graphic_figure graphicRef79681 \" href=\"UTD.htm?35/52/36672\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15288/abstract/2\">",
"     2",
"    </a>",
"    ]. As an example, patients with very \"low\" level (sacral) myelomeningocele may have unfavorable bladder dynamics even if lower extremity function is normal. Therefore, all patients with spina bifida should be evaluated periodically with ultrasonography and urodynamic studies, as described below. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/7/28793?source=see_link&amp;anchor=H3#H3\">",
"     \"Etiology and clinical features of bladder dysfunction in children\", section on 'Normal voiding'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ASSESSMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with myelomeningocele are diagnosed as newborns. For these patients, an ultrasound of the kidneys and bladder should be performed shortly after birth. This study detects the presence of hydronephrosis or hydroureter, and assesses bladder wall thickness and distension [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15288/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. The ultrasound should be performed after the newborn physiologic intravascular volume depletion has resolved (after day three of life).",
"   </p>",
"   <p>",
"    Prior to discharge from the hospital, or soon thereafter, the function of the neurogenic bladder should be evaluated with the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Voiding cystourethrogram (VCUG), which will rule out or document vesicoureteral reflux, and assess the bladder wall (smooth versus trabeculated), bladder capacity, and post void residual (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef71941 \" href=\"UTD.htm?36/9/37009\">",
"       image 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Cystometrogram (CMG) and electromyogram (EMG) (urodynamic studies), which measure bladder pressures during filling and voiding and the function of the bladder neck and external sphincter during filling and voiding (",
"      <a class=\"graphic graphic_figure graphicRef78239 \" href=\"UTD.htm?13/1/13330\">",
"       figure 2",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?14/59/15288/abstract/3-5\">",
"       3-5",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A normal bladder will be smooth walled, without vesicoureteral reflux, will fill and empty at low pressure, and upon voiding will exhibit coordinated of the bladder contraction with pelvic floor relaxation. A neurogenic bladder may exhibit problems with any or all of these normal bladder functions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/50/25384?source=see_link&amp;anchor=H19#H19\">",
"     \"Evaluation and diagnosis of bladder dysfunction in children\", section on 'Urodynamic testing'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The same evaluation should be performed in patients who present after the newborn period.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with myelomeningocele should be evaluated with renal and bladder ultrasounds and urologic studies periodically throughout life (",
"    <a class=\"graphic graphic_table graphicRef52561 \" href=\"UTD.htm?19/13/19676\">",
"     table 1",
"    </a>",
"    ). These studies monitor for changes in urinary tract function and anatomy, and guide treatment decisions. Urinary tract changes may occur for any of the following reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bladder function may change within the first few months of life [",
"      <a class=\"abstract\" href=\"UTD.htm?14/59/15288/abstract/4\">",
"       4",
"      </a>",
"      ], probably because of healing after the initial spine closure at birth.",
"     </li>",
"     <li>",
"      The capacity of a neurogenic bladder may not grow as the child grows, as normal bladders do. As an example, an infant bladder that accommodates 75 cc of urine might be sufficient for an infant but not for a five year old who requires twice that capacity.",
"     </li>",
"     <li>",
"      Lower urinary tract function can change during childhood due to shunt malfunction or development of a tethered spinal cord [",
"      <a class=\"abstract\" href=\"UTD.htm?14/59/15288/abstract/6\">",
"       6",
"      </a>",
"      ]. Surgical release of a tethered cord can be successful in improving urological function and will prevent further neurologic sequelae [",
"      <a class=\"abstract\" href=\"UTD.htm?14/59/15288/abstract/7,8\">",
"       7,8",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/46/26344?source=see_link&amp;anchor=H10#H10\">",
"       \"Overview of the management of myelomeningocele (spina bifida)\", section on 'Neurologic complications'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A patient's adherence to a regimen of intermittent catheterization and medication may vary.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Ultrasound",
"    </span>",
"    &nbsp;&mdash;&nbsp;After the baseline evaluation at birth, the renal and bladder ultrasound should be repeated at three to four months of age, after the recovery from the back surgery is complete and post-surgical swelling has subsided. The findings of hydronephrosis, hydroureter, abnormal bladder wall thickness, or excessive post-void residual volume suggest abnormal voiding mechanics and a risk for chronic renal disease. The study should then be repeated every three months in the first year of life, every six months in the second year, and then every year thereafter. The ultrasound should be performed more frequently if non-compliance with clean intermittent catheterization (CIC) is suspected or in the setting of a particularly high risk bladder. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/50/25384?source=see_link&amp;anchor=H13#H13\">",
"     \"Evaluation and diagnosis of bladder dysfunction in children\", section on 'Ultrasonography'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     VCUG, CMG, and EMG (video-urodymamics)",
"    </span>",
"    &nbsp;&mdash;&nbsp;A voiding cystourethrogram (VCUG) (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef71941 \" href=\"UTD.htm?36/9/37009\">",
"     image 1",
"    </a>",
"    ), cystometrogram, and electromyogram (",
"    <a class=\"graphic graphic_figure graphicRef78239 \" href=\"UTD.htm?13/1/13330\">",
"     figure 2",
"    </a>",
"    ) are recommended at birth, ages three to four months, one year, around two to three years of age (because this is a typical time for toilet training), and every two years thereafter (",
"    <a class=\"graphic graphic_table graphicRef52561 \" href=\"UTD.htm?19/13/19676\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15288/abstract/6,9\">",
"     6,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, because changes in lower urinary tract function may be the first sign of spinal cord tethering, urinary tract function utilizing video-urodynamics should be reevaluated if there is a change in urinary continence, new ultrasound findings such as hydronephrosis, or recurrent urinary tract infections. In addition, urodynamic studies may be repeated to assess the effectiveness of an intervention or if there is question of other neurogenic changes, such as changes in lower extremity function. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/50/25384?source=see_link&amp;anchor=H19#H19\">",
"     \"Evaluation and diagnosis of bladder dysfunction in children\", section on 'Urodynamic testing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Other studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urinalysis and urine culture should be performed only if there are symptoms of a urinary tract infection. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Urinary tract infections'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Baseline blood work for renal function (blood urea nitrogen and creatinine) should be performed in infancy, and every few years thereafter [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15288/abstract/4\">",
"     4",
"    </a>",
"    ]. If there are recurrent urinary tract infections or significant bilateral hydronephrosis, it should be done more often.",
"   </p>",
"   <p>",
"    We perform renal scintiscans (using DMSA) as a baseline study in patients with significant abnormalities of the upper tract on the ultrasound or those with unfavorable urodynamics. These scans also may be helpful in patients with recurrent urinary tract infections, to assess for scarring of the kidneys [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15288/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/30/32231?source=see_link&amp;anchor=H16#H16\">",
"     \"Evaluation of congenital anomalies of the kidney and urinary tract (CAKUT)\", section on 'Static renal scan'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Bowel assessment should be made at the same intervals as the ultrasound, assessing for signs and symptoms of stool retention and incontinence. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/46/26344?source=see_link&amp;anchor=H17#H17\">",
"     \"Overview of the management of myelomeningocele (spina bifida)\", section on 'Bowel management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goals for urologic management of myelomeningocele are to preserve renal function and for the patient to have independent continence of bowel and bladder at a developmentally appropriate age.",
"   </p>",
"   <p>",
"    Management is based on ultrasound, symptoms, and urodynamic findings, as well as psychosocial assessment of readiness. Clean intermittent catheterization (CIC) is recommended for all patients with neurogenic bladder. Anticholinergic agents are added for patients with high pressure bladders or hyperreflexic bladders. For patients with vesicoureteral reflux, anticholinergics are also used, and in some cases prophylactic antibiotics are added.",
"   </p>",
"   <p>",
"    A variety of surgical approaches may be helpful for patients who fail medical treatment for neurogenic bladder, or to facilitate self-management and continence (see",
"    <a class=\"local\" href=\"#H15\">",
"     'Surgery'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Clean intermittent catheterization",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend beginning CIC at birth for all infants with neurogenic bladder [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15288/abstract/4\">",
"     4",
"    </a>",
"    ]. The goal of CIC is to reduce the risk of urinary tract infection and overdistension of the bladder, which can lead to hydronephrosis, vesicoureteral reflux and chronic renal disease.",
"   </p>",
"   <p>",
"    There are several important reasons for early initiation of CIC:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Early initiation of CIC may improve outcomes as compared with later initiation of CIC. In a case series reporting outcomes after at least 11 years of CIC, initiating CIC early (&lt;1 year old) was associated with less deterioration of the urinary tract as compared with late treatment initiation (&gt;3 years old) [",
"      <a class=\"abstract\" href=\"UTD.htm?14/59/15288/abstract/11\">",
"       11",
"      </a>",
"      ]. Other observational studies suggest similar benefits from early initiation of CIC, and some suggest that there is additional advantage to initiating treatment during the first three months of life [",
"      <a class=\"abstract\" href=\"UTD.htm?14/59/15288/abstract/12-14\">",
"       12-14",
"      </a>",
"      ]. Consistent use of CIC regimens has reduced the need for bladder augmentation [",
"      <a class=\"abstract\" href=\"UTD.htm?14/59/15288/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Most affected individuals will eventually require CIC to attain continence or protect the kidneys, and it is easier to start a CIC program in infancy. Children who were started on CIC as infants appear to tolerate and be more compliant with the CIC than children who begin at a later age. It is more difficult to start a CIC program on a five year old than a child that has previously been catheterized. Most children can perform CIC independently by five years of age if initiated during infancy.",
"     </li>",
"     <li>",
"      Clean intermittent self-catheterization has very few complications. In a study of 31 females followed to 10 to 19 years of CIC (with or without anticholinergic treatment), only minor complications were seen. These were least likely to occur when catheters size 12 French or larger were used, and when self-catheterization was performed instead of assisted catheterization [",
"      <a class=\"abstract\" href=\"UTD.htm?14/59/15288/abstract/15\">",
"       15",
"      </a>",
"      ]. Complication rates were also low in boys [",
"      <a class=\"abstract\" href=\"UTD.htm?14/59/15288/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Urinary tract infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urinary tract infections are a common concern in individuals who perform CIC. Bacterial colonization, with abnormalities on urinalysis and urine culture, is often seen. Urinalysis and urine cultures should only be performed, and positive results subsequently treated, in symptomatic patients. Approximately 70 percent of patients performing CIC will have bacteriuria, but will be asymptomatic and not require treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15288/abstract/17\">",
"     17",
"    </a>",
"    ]. Only 5 percent develop symptomatic UTI requiring treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15288/abstract/18\">",
"     18",
"    </a>",
"    ]. Simple cloudy or smelly urine can usually be treated with increasing fluids and performing CIC every hour for three to four hours.",
"   </p>",
"   <p>",
"    Symptoms requiring urine culture and subsequent treatment include pain with CIC, gross hematuria, back or abdominal pain, lethargy, fever,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    vomiting. Treatment for symptomatic urinary tract infection in patients with myelomeningocele is similar to that for any other child with a urinary tract infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/1/27674?source=see_link&amp;anchor=H2#H2\">",
"     \"Acute management, imaging, and prognosis of urinary tract infections in infants and children older than one month\", section on 'Overview'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    After the infection is treated, a thorough history should be obtained to assess for cause of the infection. If warranted by the history, an ultrasound",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    urodynamic evaluation should be performed. Possible triggers for a urinary tract infection are noncompliance with the treatment regimen, constipation, a change in bladder dynamics (which may be caused by spinal cord tethering) or a need for adjustment of a treatment regimen.",
"   </p>",
"   <p>",
"    Some patients will continue to have urinary tract deterioration despite an optimal regimen of CIC and anticholinergic medications. In this case, nocturnal bladder emptying can be helpful. This is achieved by using a continuously draining catheter during sleep or through scheduled nighttime CIC. Among 19 children treated with nocturnal bladder emptying, 15 had clinical benefit (decrease in hydronephrosis, fewer urinary tract infections, increase in bladder capacity, or improved urinary continence) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15288/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. If nocturnal bladder emptying is unsuccessful, augmentation cystoplasty may be needed in order to achieve continence",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    preserve renal function. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Bladder augmentation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Anticholinergics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anticholinergic medication is appropriate for patients with myelomeningocele who have high pressure bladders, hyperreflexic bladders,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    vesicoureteral reflux (VUR). In these patients, VUR is secondary in nature, because it is caused by the intravesicular pressure of the neurogenic bladder. The management of secondary VUR differs from that of primary VUR, which occurs in a patient without neurogenic bladder. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/10/3242?source=see_link\">",
"     \"Presentation, diagnosis, and clinical course of vesicoureteral reflux\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with secondary VUR should be treated with an anticholinergic agent to lower filling pressures, CIC to prevent overfill, and, in some cases, prophylactic antibiotics to prevent infection [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15288/abstract/9,21\">",
"     9,21",
"    </a>",
"    ]. The efficacy of this regimen was demonstrated in a sequential nonrandomized study, in which patients with neurogenic bladder were treated with clean intermittent catheterization and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/11/40117?source=see_link\">",
"     oxybutynin",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15288/abstract/21\">",
"     21",
"    </a>",
"    ]. During five years of follow-up, the upper urinary tract deteriorated less often in the treated group as compared with historical controls (8 versus 48 percent). Similar results were seen in a large case series in which only 3 percent of children treated with early initiation of CIC and anticholinergics had renal scarring or partial loss of renal function [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15288/abstract/13\">",
"     13",
"    </a>",
"    ]. Of note, initiation of treatment later in infancy (eg, in patients with unrecognized spina bifida) appeared to be associated with higher rates of renal scarring. This compares favorably to the high rates of renal parenchymal damage reported in older series in which children were managed less aggressively [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15288/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. In one such series, 13 percent of children developed cortical damage by age two, and 27 percent by age 10 [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15288/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For an anticholinergic agent, we typically use",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/11/40117?source=see_link\">",
"     oxybutynin",
"    </a>",
"    at the following doses:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For infants &lt;12 months of age, 0.1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      orally three times a day (available as Ditropan syrup, 1",
"      <span class=\"nowrap\">",
"       mg/mL).",
"      </span>",
"     </li>",
"     <li>",
"      For children one to five years of age, 0.2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per dose three times a day (or 1 mg per year of age per dose).",
"     </li>",
"     <li>",
"      For children &ge;5 years old, we use",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/11/40117?source=see_link\">",
"       oxybutynin",
"      </a>",
"      tablets (Ditropan), 5 mg orally three times a day.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For children &ge;5 years old, the extended release preparation (Ditropan XL) may be used, beginning with 5 mg daily and titrated to effect (to a maximum dose of 20 mg daily). Ditropan is also available as a transdermal patch. An alternative anticholinergic agent is",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/28/2502?source=see_link\">",
"     tolterodine",
"    </a>",
"    (Detrol) in a dose of 1 to 2 mg by mouth twice daily or the long-acting preparation (Detrol LA), 2 to 4 mg by mouth once daily.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of prophylactic antibiotics at birth in patients with myelomeningocele remains controversial. This is also true for myelomeningocele patients with vesicoureteral reflux. Evidence for or against the use of prophylactic antibiotics in myelomeningocele patents with reflux is lacking. We believe the focus of treatment should be to assure efficient bladder emptying by intermittent catheterization and safe bladder pressures by the addition of anticholinergic medication when indicated by urodynamic studies. We reserve the use of antibiotic prophylaxis to the rare patient that has symptomatic urinary tract infections (significant bacteriuria with clinical symptoms such as fever and leukocyturia) in the presence of vesicoureteral reflux, despite optimization of bladder function with CIC and anticholinergic medication.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Latex precautions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with myelomeningocele are at risk of developing latex allergies if they are repeatedly exposed to latex during intermittent catheterization or surgical procedures. Therefore, we recommend that latex exposure should be avoided throughout life, by instituting \"latex precautions\" from birth. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/46/26344?source=see_link\">",
"     \"Overview of the management of myelomeningocele (spina bifida)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Bowel management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most individuals with neurogenic bladder also have neurogenic bowel, causing slow motility",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    laxity of the anal sphincter, with associated constipation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    incontinence. The goal of a continence program for neurogenic bowel is to prevent constipation and achieve timed elimination of stool through the use of oral laxatives, suppositories, and enemas; these methods are used singly or in combination. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/46/26344?source=see_link&amp;anchor=H17#H17\">",
"     \"Overview of the management of myelomeningocele (spina bifida)\", section on 'Bowel management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several surgical procedures are used to manage neurogenic bladder in patients with myelomeningocele; these are directed at preventing renal complications, promoting continence and facilitating self-catheterization.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Ureteral reimplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;This procedure is rarely necessary. It is occasionally used in selected patients with persistent reflux and upper tract deterioration, or in those with recurrent urinary tract infections despite an optimal regimen of clean intermittent catheterization, anticholinergics, and prophylactic antibiotics [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15288/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ureteral implantation should be considered cautiously for patients with neurogenic bladder. In these patients, the reflux is often caused by increased bladder pressures rather than by incompetent or inadequate closure of the ureterovesical junction. It is important to optimize medical treatment for the neurogenic bladder before considering ureteral reimplantation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Vesicostomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A vesicostomy is an incontinent diversion of the bladder to the lower abdominal wall. Vesicostomy is rarely indicated in this patient population. This procedure is performed for bladder drainage in infants with high bladder pressure who have failed a regimen of clean intermittent catheterization and anticholinergic medication [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15288/abstract/24\">",
"     24",
"    </a>",
"    ]. The failure may be caused by poor adherence to the medical regimen, or by a particularly small bladder capacity. Vesicostomy is usually used for temporary diversion until the patient or family is able to adhere to the regimen, or until the child is old enough to undergo bladder augmentation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15288/abstract/25,26\">",
"     25,26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Bladder augmentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;This procedure is performed in individuals who, despite CIC and anticholinergic medications, continue to have very high bladder pressures and need a larger bladder capacity to reduce this pressure, and thus preserve their renal function. Bladder augmentation also may be beneficial for patients with severe incontinence that is refractory to medical management. In this procedure, a detubularized segment of intestine (usually ileum) is added to the bladder to increase capacity and lower pressure. In the past, gastric segments were used. However, these gastric-derived patches tended to cause problems with the gastric acid secretion (hematuria and dysuria) and have increased risk of fatal cancer developing 8 to 12 years after the augmentation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15288/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Bladder augmentation does not appear to affect linear growth or bone density [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15288/abstract/28\">",
"     28",
"    </a>",
"    ]. Serum bicarbonate levels are lower and chloride levels are higher in children who have ileal augmentation, but not for those with gastric patches. Other complications include bladder calculi, bladder rupture, and excessive mucus in the urine that may lead to catheter obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15288/abstract/18\">",
"     18",
"    </a>",
"    ]. In order to prevent excessive mucous, patients with augmented bladders must perform bladder irrigations.",
"   </p>",
"   <p>",
"    Of concern, there have been a few documented cases of cancer in the augmented bladder, occurring many years after the surgery. Therefore, cystoscopy is now recommended for cancer surveillance in all patients who have had augmentation cystoplasty; we recommend performing this bi-annually beginning ten years after the augmentation procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15288/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another approach to bladder augmentation that has been attempted is a bladder auto-augmentation, where part of the musculature of the bladder wall is removed; however, this has proven to be unsuccessful in this patient population [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15288/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients who have undergone bladder augmentation surgery have an increased risk of Vitamin B deficiency; therefore, we recommend annual laboratory evaluation for vitamin B12 deficiency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Bladder neck/outlet surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the bladder outlet is weak,",
"    <span class=\"nowrap\">",
"     outlet/bladder",
"    </span>",
"    neck surgery can be performed to add resistance and gain urinary continence. There are various types of bladder",
"    <span class=\"nowrap\">",
"     neck/outlet",
"    </span>",
"    surgery, including artificial urinary sphincters and bladder neck slings, and the choice depends on individual characteristics of the patient, although most surgeons begin with a bladder neck sling because of the long-term negative sequela associated with artificial urinary sphincters.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Continent catheterizable stoma surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;A patient who is unable to catheterize their own urethra may benefit from a continent abdominal catheterizable channel such as an appendicovesicostomy (Mitrofanoff) or ileovesicostomy (Monti). The channel is constructed between the bladder and the skin utilizing appendix or bowel with the stoma placed at the level of the umbilicus or on the lower abdomen [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15288/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. This location is more accessible than the urethra, and reduces the time required for clean intermittent catheterization, especially in females with lesions at the thoracic level. The most common complication is stenosis or leaking of the stoma at the skin which may require dilation or surgical revision.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Neurosurgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;If an affected individual develops a tethered spinal cord, then neurosurgical intervention is warranted to preserve baseline urologic function and prevent further neurological deterioration.",
"   </p>",
"   <p>",
"    Although there have been surgical techniques described in which the neurologic defect is bypassed by creating a microanastomosis of the fifth lumbar ventral root to the third sacral ventral root [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15288/abstract/33\">",
"     33",
"    </a>",
"    ], these results await confirmation by other centers and are presently utilized only in experimental settings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Fetal intervention",
"    </span>",
"    &nbsp;&mdash;&nbsp;In utero repair of the neural tube defect has been performed in a few specialized centers. The MOMs trial, a prospective study, has shown that fetal surgery can decrease the need for placement of a ventriculo-perinatal shunt [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15288/abstract/34\">",
"     34",
"    </a>",
"    ]. Results from small case series do not show any improvement in bladder function with fetal intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15288/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/62/33767?source=see_link&amp;anchor=H12#H12\">",
"     \"Pathophysiology and clinical manifestations of myelomeningocele (spina bifida)\", section on 'Fetal surgery'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;With good urologic management, preservation of renal function and, if desired, urinary continence prior to school entry are attainable goals.",
"   </p>",
"   <p>",
"    Most patients with myelomeningocele will not be able to void normally, and will require lifelong treatment with clean intermittent catheterization (CIC), medication,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    surgery to be continent of urine and to protect the upper urinary tract [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15288/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thirty to 40 percent of children with myelomeningocele develop some degree of renal dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15288/abstract/1\">",
"     1",
"    </a>",
"    ]. Lack of coordination between the detrusor and external sphincter seems to be an important predictor of urinary tract deterioration, presumably because this condition promotes vesicoureteral reflux and high pressures to the kidneys. In a series of 36 infants with myelomeningocele, 50 percent of infants had discoordination of the detrusor and external urethral sphincter, 25 percent had synergic activity of the sphincter, and 25 percent had absent sphincter activity [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15288/abstract/9\">",
"     9",
"    </a>",
"    ]. Thirteen of the 18 infants with discoordination of the detrusor-external sphincter developed hydroureteronephrosis (72 percent), compared to two of nine with synergy and one of nine with no sphincter activity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nearly all patients with myelomeningocele have bladder dysfunction (neurogenic bladder). This can cause incontinence or urinary stasis, with recurrent urinary tract infections and progressive deterioration of the upper urinary tract. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with myelomeningocele should be evaluated with renal and bladder ultrasounds, voiding cystourethrograms (VCUG), cystometrograms (CMG), and electromyograms (EMG) periodically throughout life (",
"      <a class=\"graphic graphic_table graphicRef52561 \" href=\"UTD.htm?19/13/19676\">",
"       table 1",
"      </a>",
"      ). These studies monitor for changes in urinary tract function and anatomy, and inform treatment decisions. Urinary tract changes may occur with growth, changes in responsiveness or adherence to treatment, or development of a tethered cord. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Monitoring'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that all patients with neurogenic bladder be treated with a regular regimen of clean intermittent catheterization (CIC) (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Beginning this regimen at birth may prevent urinary tract deterioration and habituate the child to the procedure. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Clean intermittent catheterization'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend treating all patients with high intravesicular pressure and vesicoureteral reflux with anticholinergic agents in addition to CIC (rather than CIC alone) (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). The use of prophylactic antibiotics at birth in patients with myelomeningocele remains controversial. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Anticholinergics'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Antibiotics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Several surgical procedures are used to manage neurogenic bladder in patients with myelomeningocele; these are directed at preventing renal complications, promoting continence and facilitating self-catheterization. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Surgery'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15288/abstract/1\">",
"      M&uuml;ller T, Arbeiter K, Aufricht C. Renal function in meningomyelocele: risk factors, chronic renal failure, renal replacement therapy and transplantation. Curr Opin Urol 2002; 12:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15288/abstract/2\">",
"      Marshall DF, Boston VE. Does the absence of anal reflexes guarantee a \"safe bladder\" in children with spina bifida? Eur J Pediatr Surg 2001; 11 Suppl 1:S21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15288/abstract/3\">",
"      Hopps CV, Kropp KA. Preservation of renal function in children with myelomeningocele managed with basic newborn evaluation and close followup. J Urol 2003; 169:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15288/abstract/4\">",
"      de Jong TP, Chrzan R, Klijn AJ, Dik P. Treatment of the neurogenic bladder in spina bifida. Pediatr Nephrol 2008; 23:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15288/abstract/5\">",
"      Mesrobian HG, Balcom AH, Durkee CT. Urologic problems of the neonate. Pediatr Clin North Am 2004; 51:1051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15288/abstract/6\">",
"      Tarcan T, Bauer S, Olmedo E, et al. Long-term followup of newborns with myelodysplasia and normal urodynamic findings: Is followup necessary? J Urol 2001; 165:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15288/abstract/7\">",
"      Tarcan T, Onol FF, Ilker Y, et al. Does surgical release of secondary spinal cord tethering improve the prognosis of neurogenic bladder in children with myelomeningocele? J Urol 2006; 176:1601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15288/abstract/8\">",
"      Guerra LA, Pike J, Milks J, et al. Outcome in patients who underwent tethered cord release for occult spinal dysraphism. J Urol 2006; 176:1729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15288/abstract/9\">",
"      Bauer SB, Hallett M, Khoshbin S, et al. Predictive value of urodynamic evaluation in newborns with myelodysplasia. JAMA 1984; 252:650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15288/abstract/10\">",
"      Shiroyanagi Y, Suzuki M, Matsuno D, Yamazaki Y. The significance of 99mtechnetium dimercapto-succinic acid renal scan in children with spina bifida during long-term followup. J Urol 2009; 181:2262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15288/abstract/11\">",
"      Kochakarn W, Ratana-Olarn K, Lertsithichai P, Roongreungsilp U. Follow-up of long-term treatment with clean intermittent catheterization for neurogenic bladder in children. Asian J Surg 2004; 27:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15288/abstract/12\">",
"      Edelstein RA, Bauer SB, Kelly MD, et al. The long-term urological response of neonates with myelodysplasia treated proactively with intermittent catheterization and anticholinergic therapy. J Urol 1995; 154:1500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15288/abstract/13\">",
"      Dik P, Klijn AJ, van Gool JD, et al. Early start to therapy preserves kidney function in spina bifida patients. Eur Urol 2006; 49:908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15288/abstract/14\">",
"      Wu HY, Baskin LS, Kogan BA. Neurogenic bladder dysfunction due to myelomeningocele: neonatal versus childhood treatment. J Urol 1997; 157:2295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15288/abstract/15\">",
"      Lindehall B, Abrahamsson K, Jodal U, et al. Complications of clean intermittent catheterization in young females with myelomeningocele: 10 to 19 years of followup. J Urol 2007; 178:1053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15288/abstract/16\">",
"      Lindehall B, Abrahamsson K, Hj&auml;lm&aring;s K, et al. Complications of clean intermittent catheterization in boys and young males with neurogenic bladder dysfunction. J Urol 2004; 172:1686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15288/abstract/17\">",
"      Schlager TA, Clark M, Anderson S. Effect of a single-use sterile catheter for each void on the frequency of bacteriuria in children with neurogenic bladder on intermittent catheterization for bladder emptying. Pediatrics 2001; 108:E71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15288/abstract/18\">",
"      Joseph DB, Bauer SB, Colodny AH, et al. Clean, intermittent catheterization of infants with neurogenic bladder. Pediatrics 1989; 84:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15288/abstract/19\">",
"      Koff SA, Gigax MR, Jayanthi VR. Nocturnal bladder emptying: a simple technique for reversing urinary tract deterioration in children with neurogenic bladder. J Urol 2005; 174:1629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15288/abstract/20\">",
"      Kaefer M, Pabby A, Kelly M, et al. Improved bladder function after prophylactic treatment of the high risk neurogenic bladder in newborns with myelomentingocele. J Urol 1999; 162:1068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15288/abstract/21\">",
"      Kasabian NG, Bauer SB, Dyro FM, et al. The prophylactic value of clean intermittent catheterization and anticholinergic medication in newborns and infants with myelodysplasia at risk of developing urinary tract deterioration. Am J Dis Child 1992; 146:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15288/abstract/22\">",
"      Lewis MA, Webb NJ, Stellman-Ward GR, Bannister CM. Investigative techniques and renal parenchymal damage in children with spina bifida. Eur J Pediatr Surg 1994; 4 Suppl 1:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15288/abstract/23\">",
"      Brown S, Marshall D, Patterson D, Cunningham AM. Chronic pyelonephritis in association with neuropathic bladder. Eur J Pediatr Surg 1999; 9 Suppl 1:29.",
"     </a>",
"    </li>",
"    <li>",
"     Kaefer, M, Bauer, SB. The surgical correction of incontinence in myelodysplastic children. In: Urologic Surgery in Infants and Children, 1st ed, King, LR (Ed), WB Saunders, Philadelphia 1998. p.119.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15288/abstract/25\">",
"      Morrisroe SN, O'Connor RC, Nanigian DK, et al. Vesicostomy revisited: the best treatment for the hostile bladder in myelodysplastic children? BJU Int 2005; 96:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15288/abstract/26\">",
"      Hutcheson JC, Cooper CS, Canning DA, et al. The use of vesicostomy as permanent urinary diversion in the child with myelomeningocele. J Urol 2001; 166:2351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15288/abstract/27\">",
"      Miguel C, Rafael G, Yuval B, et al. Complications after use of gastric segments for lower urinary tract reconstruction. J Urol 2012; In press.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15288/abstract/28\">",
"      Mingin GC, Nguyen HT, Mathias RS, et al. Growth and metabolic consequences of bladder augmentation in children with myelomeningocele and bladder exstrophy. Pediatrics 2002; 110:1193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15288/abstract/29\">",
"      Soergel TM, Cain MP, Misseri R, et al. Transitional cell carcinoma of the bladder following augmentation cystoplasty for the neuropathic bladder. J Urol 2004; 172:1649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15288/abstract/30\">",
"      MacNeily AE, Afshar K, Coleman GU, Johnson HW. Autoaugmentation by detrusor myotomy: its lack of effectiveness in the management of congenital neuropathic bladder. J Urol 2003; 170:1643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15288/abstract/31\">",
"      Cain MP, Casale AJ, King SJ, Rink RC. Appendicovesicostomy and newer alternatives for the Mitrofanoff procedure: results in the last 100 patients at Riley Children's Hospital. J Urol 1999; 162:1749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15288/abstract/32\">",
"      Cain MP, Casale AJ, Rink RC. Initial experience using a catheterizable ileovesicostomy (Monti procedure) in children. Urology 1998; 52:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15288/abstract/33\">",
"      Xiao CG, Du MX, Li B, et al. An artificial somatic-autonomic reflex pathway procedure for bladder control in children with spina bifida. J Urol 2005; 173:2112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15288/abstract/34\">",
"      Adzick NS, Thom EA, Spong CY, et al. A randomized trial of prenatal versus postnatal repair of myelomeningocele. N Engl J Med 2011; 364:993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15288/abstract/35\">",
"      Lee NG, Gomez P, Uberoi V, et al. In utero closure of myelomeningocele does not improve lower urinary tract function. J Urol 2012; 188:1567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15288/abstract/36\">",
"      Holzbeierlein J, Pope JC IV, Adams MC, et al. The urodynamic profile of myelodysplasia in childhood with spinal closure during gestation. J Urol 2000; 164:1336.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6209 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-41.222.196.37-1E842E28B5-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_59_15288=[""].join("\n");
var outline_f14_59_15288=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Monitoring",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Ultrasound",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - VCUG, CMG, and EMG (video-urodymamics)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Other studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Clean intermittent catheterization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Urinary tract infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Anticholinergics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Antibiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Latex precautions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Bowel management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SURGERY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Ureteral reimplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Vesicostomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Bladder augmentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Bladder neck/outlet surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Continent catheterizable stoma surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Neurosurgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Fetal intervention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6209\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6209|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?36/9/37009\" title=\"diagnostic image 1\">",
"      Defining the bladder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6209|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?35/52/36672\" title=\"figure 1\">",
"      Normal and abnormal voiding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?13/1/13330\" title=\"figure 2\">",
"      Normal voiding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6209|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/13/19676\" title=\"table 1\">",
"      MM urinary monitor",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/1/27674?source=related_link\">",
"      Acute management, imaging, and prognosis of urinary tract infections in infants and children older than one month",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/7/28793?source=related_link\">",
"      Etiology and clinical features of bladder dysfunction in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/50/25384?source=related_link\">",
"      Evaluation and diagnosis of bladder dysfunction in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/30/32231?source=related_link\">",
"      Evaluation of congenital anomalies of the kidney and urinary tract (CAKUT)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/46/26344?source=related_link\">",
"      Overview of the management of myelomeningocele (spina bifida)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/62/33767?source=related_link\">",
"      Pathophysiology and clinical manifestations of myelomeningocele (spina bifida)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/10/3242?source=related_link\">",
"      Presentation, diagnosis, and clinical course of vesicoureteral reflux",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_59_15289="Open-angle glaucoma: Epidemiology, clinical presentation, and diagnosis";
var content_f14_59_15289=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Open-angle glaucoma: Epidemiology, clinical presentation, and diagnosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/59/15289/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/59/15289/contributors\">",
"     Deborah S Jacobs, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/59/15289/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/59/15289/contributors\">",
"     Jonathan Trobe, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/59/15289/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/59/15289/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/59/15289/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 7, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glaucoma is a group of eye diseases traditionally characterized by elevated intraocular pressure (IOP). However, glaucoma is more accurately defined as an optic neuropathy than a disease of high pressure. In open-angle glaucoma, optic nerve damage results in a progressive loss of retinal ganglion cell axons, which is manifested initially as visual field loss and, ultimately, irreversible blindness if left untreated [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15289/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will discuss the epidemiology, clinical presentation, and diagnosis of open-angle glaucoma in adults. Glaucoma in children, angle-closure glaucoma, and treatment and prevention of open-angle glaucoma are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/31/41463?source=see_link\">",
"     \"Overview of glaucoma in infants and children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/54/9063?source=see_link\">",
"     \"Angle-closure glaucoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/2/34855?source=see_link\">",
"     \"Open-angle glaucoma: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H812842485\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are different types of glaucoma, generally categorized by the anterior chamber (iridocorneal) angle (",
"    <a class=\"graphic graphic_figure graphicRef71234 \" href=\"UTD.htm?10/60/11201\">",
"     figure 1",
"    </a>",
"    ) and the underlying etiology, if known:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Open-angle glaucoma is an optic neuropathy characterized by progressive peripheral visual field loss followed by central field loss, in a characteristic pattern. This is usually but not always in the presence of elevated intraocular pressure (IOP), perhaps in part related to increased aqueous production and decreased outflow (",
"      <a class=\"graphic graphic_figure graphicRef54950 \" href=\"UTD.htm?12/19/12595\">",
"       figure 2",
"      </a>",
"      ). The optic nerve or \"disc\" takes on a hollowed-out appearance on ophthalmoscopic examination, which is described as \"cupping.\" Cupping is associated with the loss of ganglion cell axons. &nbsp;",
"     </li>",
"     <li>",
"      Angle-closure glaucoma is characterized by narrowing or closure of the anterior chamber angle. The normal anterior chamber angle provides drainage for the aqueous humor (the fluid that fills the eyeball). When this drainage pathway is narrowed or closed, inadequate drainage leads to elevated intraocular pressure and damage to the optic nerve (",
"      <a class=\"graphic graphic_figure graphicRef59454 \" href=\"UTD.htm?39/50/40738\">",
"       figure 3",
"      </a>",
"      ). Acute angle-closure glaucoma occurs in eyes with a certain anatomical predisposition. It presents as a painful red eye and must be treated within 24 hours to prevent permanent blindness. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/54/9063?source=see_link\">",
"       \"Angle-closure glaucoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Developmental glaucoma occurs in infants and children and is discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/31/41463?source=see_link\">",
"       \"Overview of glaucoma in infants and children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/57/5016?source=see_link\">",
"       \"Primary infantile glaucoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Both open-angle and angle-closure glaucoma can be divided into primary and secondary forms. Secondary glaucoma has many subtypes with elevated IOP resulting from uveitis, trauma, glucocorticoid therapy, vasoproliferative retinopathy, or ocular syndromes such as pigment dispersion or pseudoexfoliation (the deposition of white fluffy material within the anterior segment of the eye).",
"     </li>",
"     <li>",
"      Glaucoma can also be categorized based on timing (ie, acute, subacute, and chronic).",
"     </li>",
"     <li>",
"      Mixed mechanism glaucoma refers to glaucoma with several etiologies (eg, open-angle glaucoma complicated by superimposed angle-closure, or open-angle glaucoma with superimposed uveitis).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glaucoma is the second leading cause of blindness in the world (after cataracts) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15289/abstract/2\">",
"     2",
"    </a>",
"    ] and the leading cause of blindness among African-Americans [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15289/abstract/3\">",
"     3",
"    </a>",
"    ]. Open-angle glaucoma is the most common type of glaucoma among populations of European or African descent, whereas angle-closure glaucoma is more common among populations of Asian descent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15289/abstract/2\">",
"     2",
"    </a>",
"    ]. It is estimated that there are 44.7 million people with open-angle glaucoma worldwide in 2010, and that this number will increase to 58.6 million in 2020 [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15289/abstract/4\">",
"     4",
"    </a>",
"    ]. It is estimated that there are 2.8 million people with open-angle glaucoma in the United States (US) in 2010 [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15289/abstract/4\">",
"     4",
"    </a>",
"    ], and that the number will increase to 3.4 million in 2020 [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15289/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with open-angle glaucoma report decreased quality-of-life and difficulties with daily functioning, including driving [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15289/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Patients with glaucoma are also more likely to report falls and motor vehicle collisions [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15289/abstract/8\">",
"     8",
"    </a>",
"    ]. One meta-analysis found no association between open-angle glaucoma and all-cause mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15289/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the US, the cost of glaucoma to society has been estimated to be about $1.5 billion per year, including benefits, lost tax revenues, and health expenses [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15289/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major risk factors for developing open-angle glaucoma include age, black race, family history, and elevated intraocular pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15289/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Age &mdash; The incidence of open-angle glaucoma increases with age, particularly in patients of Caucasian and African ancestry [",
"      <a class=\"abstract\" href=\"UTD.htm?14/59/15289/abstract/13-15\">",
"       13-15",
"      </a>",
"      ]. The prevalence of open-angle glaucoma is below 1 percent in individuals under 55 years of age, approaches 2 percent at age 65, and reaches approximately 4 percent at age 80 [",
"      <a class=\"abstract\" href=\"UTD.htm?14/59/15289/abstract/5\">",
"       5",
"      </a>",
"      ]. The rate of blindness from open-angle glaucoma also increases with age [",
"      <a class=\"abstract\" href=\"UTD.htm?14/59/15289/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Race &mdash; Race is an important risk factor for development and progression of open-angle glaucoma. The estimated prevalence of open-angle glaucoma is approximately three times higher in blacks, compared to whites [",
"      <a class=\"abstract\" href=\"UTD.htm?14/59/15289/abstract/5\">",
"       5",
"      </a>",
"      ]. The age-adjusted rate of blindness from glaucoma among blacks was 6.6 times that among whites, with blindness beginning 10 years earlier in blacks [",
"      <a class=\"abstract\" href=\"UTD.htm?14/59/15289/abstract/3\">",
"       3",
"      </a>",
"      ]. The incidence of open-angle glaucoma in Latinos is higher than in non-Hispanic whites, though lower than in Afro-Caribbeans [",
"      <a class=\"abstract\" href=\"UTD.htm?14/59/15289/abstract/16\">",
"       16",
"      </a>",
"      ]. Non-Hispanic white women comprise the largest group with open-angle glaucoma in the United States in 2011, but it is anticipated that this will shift to Hispanic men over the next several decades [",
"      <a class=\"abstract\" href=\"UTD.htm?14/59/15289/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Family history &mdash; Family history is a significant risk factor for open-angle glaucoma in several population studies [",
"      <a class=\"abstract\" href=\"UTD.htm?14/59/15289/abstract/18-21\">",
"       18-21",
"      </a>",
"      ]. The Baltimore Eye Survey found that the relative risk of open-angle glaucoma increased 3.7- and 2.2-fold for individuals with an affected sibling or parent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?14/59/15289/abstract/18\">",
"       18",
"      </a>",
"      ]. Several early-onset glaucoma syndromes are inherited as Mendelian dominant or recessive traits; open-angle glaucoma, however, has a complex inheritance pattern, with the likelihood that multiple genes interact with environmental factors [",
"      <a class=\"abstract\" href=\"UTD.htm?14/59/15289/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Elevated intraocular pressure (IOP) &mdash; There is a large body of literature illustrating the association between elevated IOP and both development and progression of open-angle glaucoma [",
"      <a class=\"abstract\" href=\"UTD.htm?14/59/15289/abstract/21-26\">",
"       21-26",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      As an example, the Early Manifest Glaucoma Trial followed 255 patients with a diagnosis of open-angle glaucoma over a mean of eight years; mean IOP was a significant risk factor for progression of glaucoma (HR 1.11, 95% CI 1.06-1.17), even when IOP was within the \"normal\" range of 8 to 22 mg Hg [",
"      <a class=\"abstract\" href=\"UTD.htm?14/59/15289/abstract/27\">",
"       27",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Approximately one-sixth of patients in the US with otherwise characteristic open-angle glaucoma will have a consistently normal IOP [",
"      <a class=\"abstract\" href=\"UTD.htm?14/59/15289/abstract/28\">",
"       28",
"      </a>",
"      ]. These patients constitute a subgroup commonly referred to as low-tension or normal-tension glaucoma. While a small proportion of open-angle glaucoma in the US may be classified as normal tension, the majority of patients with open-angle glaucoma in Asia have normal tension glaucoma [",
"      <a class=\"abstract\" href=\"UTD.htm?14/59/15289/abstract/29\">",
"       29",
"      </a>",
"      ]. In contrast, many patients with elevated pressures never develop the optic nerve and field changes characteristic of glaucoma [",
"      <a class=\"abstract\" href=\"UTD.htm?14/59/15289/abstract/22,23\">",
"       22,23",
"      </a>",
"      ]. Thus, although high pressure is clearly associated with open-angle glaucoma, it is neither necessary nor sufficient for the diagnosis and is therefore termed a \"risk factor\" for the condition.",
"     </li>",
"     <li>",
"      Other factors &mdash; Other possible risk factors for developing open-angle glaucoma include myopia, pseudoexfoliation, low diastolic perfusion pressure, cardiovascular disease, systemic hypertension, diabetes mellitus, and hypothyroidism [",
"      <a class=\"abstract\" href=\"UTD.htm?14/59/15289/abstract/30-37\">",
"       30-37",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although risk factors for the development of open-angle glaucoma have been well-documented, risk factors for progression of open-angle glaucoma have not been as conclusively established [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15289/abstract/38\">",
"     38",
"    </a>",
"    ]. Results conflict whether fluctuation in IOP is predictive of glaucoma progression [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15289/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. Even in patients with documented findings of glaucoma on comprehensive eye examination (eg, visual field deficits, optic disc changes), it is unclear which patients go on to develop loss of visual acuity and blindness [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15289/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of primary open-angle glaucoma is not clear. Optic nerve axon loss may be related to ganglion cell susceptibility, microcirculatory deficiency at the optic nerve head, or extracellular matrix factors [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15289/abstract/11,40\">",
"     11,40",
"    </a>",
"    ]. These factors may play a combined role: circulatory or extracellular matrix factors could account for both high pressures and axon loss; variation in axon susceptibility might explain why the disease state does not correlate well with elevated IOP [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15289/abstract/41\">",
"     41",
"    </a>",
"    ]. It is not clear if elevated IOP is caused by factors related to aqueous production, aqueous outflow, or to anatomic or physiologic features of the trabecular meshwork and other outflow structures. Systemic factors may also play a role, as there is some evidence that cardiac autonomic dysfunction, as measured by heart rate variability, may correlate with the presence of normal pressure glaucoma [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15289/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mutations in the myocilin gene (MYOC) have been identified in about 4 percent of adults with open-angle glaucoma and more than 10 percent of cases of juvenile open-angle glaucoma, a rare autosomal dominant condition with glaucoma onset between 3 and 40 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15289/abstract/11\">",
"     11",
"    </a>",
"    ]. MYOC mutations alter the myocilin protein. Myocilin-associated glaucoma is characterized by elevated IOP, with IOP &gt;40 mmHg in some patients with juvenile open-angle glaucoma. Myocilin is produced in the ciliary body and trabecular meshwork, but its precise role in regulating intraocular pressure is unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals with open-angle glaucoma rarely experience symptoms. Thus, open-angle glaucoma is generally detected incidentally during comprehensive ophthalmic examination. This is in contrast to angle-closure glaucoma in which patients present with symptoms and signs including loss of visual acuity, pain, conjunctival erythema, and corneal edema. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/54/9063?source=see_link&amp;anchor=H9#H9\">",
"     \"Angle-closure glaucoma\", section on 'Clinical presentation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    High elevations of intraocular pressure (IOP), up to 40 mmHg in patients with open-angle glaucoma, generally cause no pain, redness, or visual symptoms. There is no loss of visual acuity as long as central vision is preserved. Central visual field loss is a late manifestation of open-angle glaucoma, usually preceded by ganglion cell loss and optic nerve damage. Some patients are unaware of field loss even when it has progressed to central \"tunnel vision\" of 10 to 20 degrees. Visual field loss cannot be recovered once it has occurred.",
"   </p>",
"   <p>",
"    The mean progression rate from a full field of vision to blindness takes approximately 25 years in untreated patients [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15289/abstract/43\">",
"     43",
"    </a>",
"    ]. However, it is important to note that the median progression rate is much slower (approximately 70 years), since only a small minority of patients progress rapidly to blindness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H447095064\">",
"    <span class=\"h1\">",
"     SCREENING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intraocular pressure (IOP) testing remains the most available and best studied means of screening for glaucoma. However, as mentioned below, no diagnostic test has ideal sensitivity or specificity for screening in the general population, alone or in combination [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15289/abstract/44\">",
"     44",
"    </a>",
"    ]. It remains controversial which populations should be screened, what screening tests should be performed, and with what frequency. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1320774\">",
"    <span class=\"h2\">",
"     Evidence for treating elevated intraocular pressure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Randomized trials that investigated the effect of lowering IOP in patients with elevated IOP without visual defects have found some benefit in delaying or preventing the onset of open-angle glaucoma [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15289/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. In a meta-analysis of five randomized trials in adults with elevated IOP (n = 2318), those randomly assigned to topical IOP lowering medication were less likely to develop open-angle glaucoma compared to those randomly assigned to placebo (HR 0.56, 95% CI 0.39-0.81) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15289/abstract/45\">",
"     45",
"    </a>",
"    ]. The study further estimated that 12 subjects with elevated IOP would need to be treated to prevent one case of glaucoma within five years of treatment. One large randomized trial (n = 1636) found that IOP lowering medication reduced the risk of both optic disc deterioration (HR 0.36, 95% CI 0.23-0.56) and the perhaps more clinically important outcome of visual field abnormalities (HR 0.45, 95% CI 0.27-0.76) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15289/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since the prevalence of elevated IOP in the general population is approximately 4 percent among individuals age &ge;40 years [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15289/abstract/48\">",
"     48",
"    </a>",
"    ] and 12 patients would be needed to treat to prevent one case of glaucoma, 300 individuals would need to be screened to prevent one case of glaucoma within five years of treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1320003\">",
"    <span class=\"h2\">",
"     Cost-effectiveness",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the absence of randomized trials assessing screening strategies, several studies have attempted to determine the cost-effectiveness of glaucoma screening, with more recent studies using Markov modelling [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15289/abstract/49-52\">",
"     49-52",
"    </a>",
"    ]. One study in the United Kingdom found that neither IOP measurement alone nor comprehensive eye examination were cost-effective in subjects age &ge;40 years, but that screening in older or other higher risk populations might be cost-effective [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15289/abstract/51\">",
"     51",
"    </a>",
"    ]. Another study in Finland found that screening with combined fundus examination, visual field testing, and intraocular pressure measurement in persons age 50 to 89 was cost-effective for preventing visual disability (32,603 Euros per one year of avoided visual disability) and quality-adjusted life years (9,023 Euros per one QALY gained by screening) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15289/abstract/52\">",
"     52",
"    </a>",
"    ]. There is a great deal of uncertainty in the assumptions of these models, particularly with regard to which is the optimal screening protocol, the harms and benefits associated with early detection, and the thresholds for different treatments in relation to cost (determining follow-up, adherence, and additional testing) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15289/abstract/49,51,52\">",
"     49,51,52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H447095071\">",
"    <span class=\"h2\">",
"     Recommendations of others",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is significant variation in screening recommendations from different organizations, partly since no randomized trials have evaluated screening strategies for the prevention of open-angle glaucoma [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15289/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The American Academy of Ophthalmology (AAO) recommends a comprehensive eye examination for every patient over age 40 by an ophthalmologist or an optometrist skilled in the assessment of the optic nerve and knowledgeable about glaucoma [",
"      <a class=\"abstract\" href=\"UTD.htm?14/59/15289/abstract/28\">",
"       28",
"      </a>",
"      ]. Screening only by measuring IOP is not appropriate since a substantial number of patients with glaucomatous visual field changes have normal IOP [",
"      <a class=\"abstract\" href=\"UTD.htm?14/59/15289/abstract/22\">",
"       22",
"      </a>",
"      ]. A typical frequency for repeat evaluation for individuals between ages 40 and 60 is every three to five years for those without risk factors, and every one to two years for those with one or more risk factors such as borderline pressures, cupping, black race, and family history. The AAO also suggests periodic examination for black men and women between ages 20 to 39.",
"      <br/>",
"      <br/>",
"      After age 60, a comprehensive eye examination should be performed every one to two years. Field testing is performed by the ophthalmologist once the patient falls into the diagnostic category of \"glaucoma suspect\" based upon the other risk factors. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The US Preventive Services Task Force (USPSTF) found insufficient evidence to recommend for or against screening adults for glaucoma [",
"      <a class=\"abstract\" href=\"UTD.htm?14/59/15289/abstract/54\">",
"       54",
"      </a>",
"      ]. While they felt there was good evidence that screening could detect increased IOP and early open-angle glaucoma, and that early treatment reduces the development and progression of visual field defects, they also felt that the evidence was insufficient to determine the extent to which screening would reduce impairment in vision-related function or quality of life. They noted that harms associated with treatment for increased IOP and early open-angle glaucoma include local eye irritation and an increased risk for cataracts.",
"     </li>",
"     <li>",
"      The Canadian Task Force on the Periodic Health Examination also concluded that there was insufficient evidence to recommend for or against screening for glaucoma in the periodic health examination. Referral of high-risk individuals to a specialist was deemed \"clinically prudent\" [",
"      <a class=\"abstract\" href=\"UTD.htm?14/59/15289/abstract/55\">",
"       55",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1930221\">",
"    <span class=\"h2\">",
"     Synthesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the risk of blindness with untreated glaucoma, the effectiveness of treatment, and that early open angle glaucoma is asymptomatic, we suggest that individuals over age 40 be screened for glaucoma. Earlier screening may be appropriate for individuals with significant risk factors for glaucoma. Although the randomized trials cited in this section performed IOP-based screening only, we suggest screening with a comprehensive eye examination since individual tests such as fundus examination or measurement of intraocular pressure alone will likely fail to detect many cases of glaucoma [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15289/abstract/56-58\">",
"     56-58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glaucoma is diagnosed in patients with characteristic nerve damage on fundus examination (",
"    <a class=\"graphic graphic_picture graphicRef50075 graphicRef65935 \" href=\"UTD.htm?6/35/6714\">",
"     picture 1A-B",
"    </a>",
"    ) and visual field testing, typically in the presence of elevated intraocular pressures. Some authorities consider either characteristic optic nerve change OR visual field defects as sufficient criteria for diagnosis of open-angle glaucoma [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15289/abstract/59,60\">",
"     59,60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The American Academy of Ophthalmology (AAO) Preferred Practice Pattern defines primary open-angle glaucoma as a chronic, generally bilateral, and often asymmetrical disease, which is characterized (in at least one eye) by all of the following [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15289/abstract/28\">",
"     28",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Evidence of glaucomatous optic nerve damage from either or both of the following: the appearance of the disc or retinal nerve fiber layer (eg, thinning, cupping, or notching of the disc rim, progressive change, nerve fiber layer defects); the presence of characteristic abnormalities in the visual field (eg, arcuate defect, nasal step paracentral scotoma, generalized depression) in the absence of other causes or explanations for a field defect.",
"     </li>",
"     <li>",
"      Adult onset.",
"     </li>",
"     <li>",
"      Open, normal appearing anterior chamber angles.",
"     </li>",
"     <li>",
"      Absence of known (eg, secondary) causes of open-angle glaucoma.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H387536684\">",
"    <span class=\"h2\">",
"     Who should be referred for comprehensive eye examination?",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with abnormal cupping should be referred for a comprehensive eye examination. Any patient with high IOP detected during community-based screening or",
"    <span class=\"nowrap\">",
"     spectacle/contact",
"    </span>",
"    lens evaluation should also be referred for comprehensive eye examination. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H447092864\">",
"    <span class=\"h2\">",
"     Diagnostic tests",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H387536783\">",
"    <span class=\"h3\">",
"     Fundus examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary care clinician should be attentive to the presence of cupping seen in the fundus. Cupping describes a hollowed-out appearance of the optic nerve or \"disc\" on fundus examination. A cup whose diameter is greater than 50 percent of the vertical disc diameter is indicative of glaucoma.",
"   </p>",
"   <p>",
"    Although cupping has the highest sensitivity and specificity of any other finding on eye examination, there is no single cutoff criteria that yields sufficiently high sensitivity and specificity to make cupping a useful diagnostic test [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15289/abstract/61\">",
"     61",
"    </a>",
"    ]. One study found that ophthalmologists, using direct ophthalmoscopy, detected less than one-half of cases of glaucoma [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15289/abstract/56\">",
"     56",
"    </a>",
"    ]. Combining cupping with other diagnostic criteria increased diagnostic yield.",
"   </p>",
"   <p>",
"    Other findings on fundus examination indicative of glaucoma include thinning or notching of the disc rim, progressive change of the size or shape of the cup, and nerve fiber layer defects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Visual field testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Open-angle glaucoma ideally should be diagnosed before there is significant visual field loss. However, confrontational field testing, using the examiner&rsquo;s fingers, is not useful in the detection of glaucoma. Automated perimetry is an important diagnostic tool that is much more reliable at detecting visual field loss in glaucoma compared to confrontational field testing (",
"    <a class=\"graphic graphic_figure graphicRef82102 \" href=\"UTD.htm?22/9/22680\">",
"     figure 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15289/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are several types of automated perimetry technologies, including standard threshold automated perimetry, frequency doubling technology perimetry, and short wavelength automated perimetry [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15289/abstract/57\">",
"     57",
"    </a>",
"    ]. Automated perimetry has become the standard of care for optometric and ophthalmic practice in the detection and monitoring of glaucoma, although there is a role for careful manual perimetry in some cases, particularly in patients with advanced field loss or dementia. Reliable field testing requires comprehension and cooperation on the part of the patient. Dementia and other mental or physical problems may preclude testing in certain individuals, forcing the clinician to rely upon other variables in diagnostic and therapeutic decision-making.",
"   </p>",
"   <p>",
"    Visual field testing can be time consuming and of variable specificity and sensitivity, depending on user characteristics and the type of test being used.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Intraocular pressure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elevated intraocular pressure (IOP) alone does not establish the diagnosis of open-angle glaucoma [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15289/abstract/28,63\">",
"     28,63",
"    </a>",
"    ]. One-third to one-half of individuals with glaucoma field defects have intraocular pressures &le;21 mmHg when first detected (normal IOP 8 to 21 mmHg) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15289/abstract/64\">",
"     64",
"    </a>",
"    ]. In addition, over 90 percent of adults with pressures &gt;21 mmHg have no optic nerve damage. However, patients with elevated IOP should be referred to an ophthalmologist given their higher risk of open-angle glaucoma. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Risk factors'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    A prospective population study of risk factors associated with glaucomatous field loss found that during a period of five years, 99 percent of eyes with an initial pressure &lt;20 mmHg continued to be free of glaucomatous field defects, compared with 93 percent of eyes with an initial pressure &ge;20 mmHg [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15289/abstract/65\">",
"     65",
"    </a>",
"    ]. The sensitivity for the diagnosis of open-angle glaucoma by IOP measurement was 47.1 percent and the specificity over 90 percent at an IOP cutoff point of &gt;21 mmHg [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15289/abstract/58\">",
"     58",
"    </a>",
"    ]. The presence of either increased IOP (&gt;21 mmHg) or increased vertical",
"    <span class=\"nowrap\">",
"     cup/disc",
"    </span>",
"    ratio (&ge;0.5) increased the sensitivity to 61 percent but decreased the specificity to 84 percent. There was no cutoff value for IOP that had reasonable sensitivity and specificity as a screening tool for the diagnosis of open-angle glaucoma.",
"   </p>",
"   <p>",
"    Ophthalmologists and optometrists can measure IOP by applanation tonometry, pneumotonometry, or air-puff tonometry. Applanation tonometry is a method that determines the intraocular pressure from the force required to flatten (applanate) a constant area of the cornea (",
"    <a class=\"graphic graphic_picture graphicRef59419 \" href=\"UTD.htm?8/49/8979\">",
"     picture 2",
"    </a>",
"    ). Applanation tonometry is most accurate and less subject to artifact. All tonometry methods require specialized equipment and skill, and thus fall out of the realm of the primary care clinician. Due to the effects of central corneal thickness on the mechanics of applanation tonometry, falsely higher measurements occur in patients with thicker corneas and falsely lower measurements in those with thinner corneas [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15289/abstract/66\">",
"     66",
"    </a>",
"    ]. This can be partially corrected with pachymetry. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Pachymetry'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Schiotz tonometry is a handheld device that is relatively inexpensive, but requires frequent use for reliable results. Generalists who practice in populations that do not have access to optometric or ophthalmic care can learn Schiotz tonometry and use it in conjunction with the optic disc examination in deciding whom to treat or refer. In developed countries, it is less common for primary care providers to measure IOP.",
"   </p>",
"   <p>",
"    There is some evidence that wearing a tight necktie may temporarily increase IOP [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15289/abstract/67\">",
"     67",
"    </a>",
"    ]. The clinical implications of these findings require further study. Regardless, it is prudent to ask patients to loosen collars and ties prior to measuring IOP.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h4\">",
"     Pressure parameters for referral",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no standard criteria for referral to an ophthalmologist for patients with elevated pressures. Primary open-angle glaucoma rarely presents with IOP &gt;30mmHg, which is more common among patients with angle-closure glaucoma or secondary (rather than primary) open-angle glaucoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/54/9063?source=see_link\">",
"     \"Angle-closure glaucoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/12/17607?source=see_link\">",
"     \"Evaluation of the red eye\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following represent indications for ophthalmologic referral based on clinical practice experience:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      IOP &gt;40 mmHg: Emergency referral",
"     </li>",
"     <li>",
"      IOP 30 to 40 mmHg: Urgent referral (within 24 hours) if no symptoms suggesting acute glaucoma",
"     </li>",
"     <li>",
"      IOP 25 to 29 mmHg: Evaluation within one week",
"     </li>",
"     <li>",
"      IOP 23-24 mmHg warrants repeat measurement to confirm",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      referral for comprehensive eye examination",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These indications are not absolute, and should be interpreted in the context of patient history and examination findings. As an example, a patient with an IOP of 28 and advanced open-angle glaucoma including field loss and cupping may represent an emergency because of risk of imminent field loss, while a patient with a healthy nerve could withstand an IOP at that level for weeks with little risk of further nerve damage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Pachymetry",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pachymetry is the measurement of corneal thickness; it can be performed by ultrasound or other methods. Patients with thin corneas are at higher risk for the development of open-angle glaucoma [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15289/abstract/47,68\">",
"     47,68",
"    </a>",
"    ]. Ophthalmologists may perform pachymetry in patients with suspected or diagnosed open-angle glaucoma to further evaluate their risk for development or progression of open-angle glaucoma [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15289/abstract/69\">",
"     69",
"    </a>",
"    ]. Additionally, corneal thickness affects the results of applanation tonometry, and pachymetry may adjust for this effect. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Intraocular pressure'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Newer technologies for fundus evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several newer technologies have been developed to evaluate the optic disc and retinal nerve fiber layer. These may aid in the early detection of glaucoma, as well as other eye diseases.",
"   </p>",
"   <p>",
"    Optical coherence tomography (OCT), Heidelberg retinal tomography (HRT), and scanning laser polarimetry are non-invasive imaging techniques that analyze light reflected off the fundus [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15289/abstract/70,71\">",
"     70,71",
"    </a>",
"    ]. The need for pupil dilation varies with the particular device and the part of the fundus being studied. These tests are well-tolerated by patients. The devices generate a digital image and quantification of specific features of optic nerve head anatomy.",
"   </p>",
"   <p>",
"    One study compared OCT, HRT, scanning laser polarimetry, and conventional qualitative assessment of stereoscopic photographs of the optic disc [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15289/abstract/72\">",
"     72",
"    </a>",
"    ]. The three newer technologies performed as well as, but not better than, stereoscopic photographs. Accuracy of results from stereoscopic images is dependent on the experience and skill of the interpreter, whereas the newer technologies provide more quantitative data that is less user dependent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/35/11826?source=see_link\">",
"       \"Patient information: Age-related vision loss (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?2/13/2258?source=see_link\">",
"       \"Patient information: Glaucoma (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6892553\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Open-angle glaucoma is an optic neuropathy characterized by progressive peripheral visual field loss followed by central field loss, in a characteristic pattern. This is usually but not always in the presence of elevated intraocular pressure (IOP), perhaps in part related to increased aqueous production and decreased outflow (",
"      <a class=\"graphic graphic_figure graphicRef54950 \" href=\"UTD.htm?12/19/12595\">",
"       figure 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H812842485\">",
"       'Classification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Open-angle glaucoma is a leading cause of irreversible blindness in the world. The major risk factors for developing open-angle glaucoma include age, black race, family history, and elevated intraocular pressure. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Individuals with open-angle glaucoma rarely experience symptoms. Some patients are unaware of field loss even when it has progressed to central \"tunnel vision.\" Thus, open-angle glaucoma is generally detected incidentally on comprehensive ophthalmic examination. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that all individuals over age 40 be screened for glaucoma (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). If the decision is made to undergo screening, we suggest performing a comprehensive eye examination rather than screening with individual tests (eg, fundus examination or measurement or intraocular pressure alone) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Earlier screening may be appropriate for individuals with significant risk factors for glaucoma. (See",
"      <a class=\"local\" href=\"#H447095064\">",
"       'Screening'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with abnormal cupping on fundus examination should be referred for a comprehensive eye examination. (See",
"      <a class=\"local\" href=\"#H387536684\">",
"       'Who should be referred for comprehensive eye examination?'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Glaucoma is diagnosed in patients with characteristic nerve damage on fundus examination and on visual field testing (",
"      <a class=\"graphic graphic_picture graphicRef50075 graphicRef65935 \" href=\"UTD.htm?6/35/6714\">",
"       picture 1A-B",
"      </a>",
"      ), typically in the presence of elevated intraocular pressures. Some authorities consider either characteristic optic nerve change OR visual field defects as sufficient criteria for diagnosis of open-angle glaucoma. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15289/abstract/1\">",
"      Weinreb RN, Khaw PT. Primary open-angle glaucoma. Lancet 2004; 363:1711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15289/abstract/2\">",
"      Kingman S. Glaucoma is second leading cause of blindness globally. Bull World Health Organ 2004; 82:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15289/abstract/3\">",
"      Sommer A, Tielsch JM, Katz J, et al. Racial differences in the cause-specific prevalence of blindness in east Baltimore. N Engl J Med 1991; 325:1412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15289/abstract/4\">",
"      Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol 2006; 90:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15289/abstract/5\">",
"      Friedman DS, Wolfs RC, O'Colmain BJ, et al. Prevalence of open-angle glaucoma among adults in the United States. Arch Ophthalmol 2004; 122:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15289/abstract/6\">",
"      Ang GS, Eke T. Lifetime visual prognosis for patients with primary open-angle glaucoma. Eye (Lond) 2007; 21:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15289/abstract/7\">",
"      Richman J, Lorenzana LL, Lankaranian D, et al. Relationships in glaucoma patients between standard vision tests, quality of life, and ability to perform daily activities. Ophthalmic Epidemiol 2010; 17:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15289/abstract/8\">",
"      Haymes SA, Leblanc RP, Nicolela MT, et al. Risk of falls and motor vehicle collisions in glaucoma. Invest Ophthalmol Vis Sci 2007; 48:1149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15289/abstract/9\">",
"      Akbari M, Akbari S, Pasquale LR. The association of primary open-angle glaucoma with mortality: a meta-analysis of observational studies. Arch Ophthalmol 2009; 127:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15289/abstract/10\">",
"      Distelhorst JS, Hughes GM. Open-angle glaucoma. Am Fam Physician 2003; 67:1937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15289/abstract/11\">",
"      Kwon YH, Fingert JH, Kuehn MH, Alward WL. Primary open-angle glaucoma. N Engl J Med 2009; 360:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15289/abstract/12\">",
"      Czudowska MA, Ramdas WD, Wolfs RC, et al. Incidence of glaucomatous visual field loss: a ten-year follow-up from the Rotterdam Study. Ophthalmology 2010; 117:1705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15289/abstract/13\">",
"      Mukesh BN, McCarty CA, Rait JL, Taylor HR. Five-year incidence of open-angle glaucoma: the visual impairment project. Ophthalmology 2002; 109:1047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15289/abstract/14\">",
"      Leske MC, Heijl A, Hyman L, et al. Predictors of long-term progression in the early manifest glaucoma trial. Ophthalmology 2007; 114:1965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15289/abstract/15\">",
"      Chauhan BC, Mikelberg FS, Balaszi AG, et al. Canadian Glaucoma Study: 2. risk factors for the progression of open-angle glaucoma. Arch Ophthalmol 2008; 126:1030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15289/abstract/16\">",
"      Varma R, Wang D, Wu C, et al. Four-year incidence of open-angle glaucoma and ocular hypertension: the Los Angeles Latino Eye Study. Am J Ophthalmol 2012; 154:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15289/abstract/17\">",
"      Vajaranant TS, Wu S, Torres M, Varma R. The changing face of primary open-angle glaucoma in the United States: demographic and geographic changes from 2011 to 2050. Am J Ophthalmol 2012; 154:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15289/abstract/18\">",
"      Tielsch JM, Katz J, Sommer A, et al. Family history and risk of primary open angle glaucoma. The Baltimore Eye Survey. Arch Ophthalmol 1994; 112:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15289/abstract/19\">",
"      Wiggs JL. Genetic etiologies of glaucoma. Arch Ophthalmol 2007; 125:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15289/abstract/20\">",
"      Zegers RH, Reinders EF, de Smet MD. Primary open-angle glaucoma: the importance of family history and role of intraocular pressure. Med J Aust 2008; 188:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15289/abstract/21\">",
"      Ekstr&ouml;m C. Risk factors for incident open-angle glaucoma: a population-based 20-year follow-up study. Acta Ophthalmol 2012; 90:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15289/abstract/22\">",
"      Heijl A, Leske MC, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 2002; 120:1268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15289/abstract/23\">",
"      Nemesure B, Honkanen R, Hennis A, et al. Incident open-angle glaucoma and intraocular pressure. Ophthalmology 2007; 114:1810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15289/abstract/24\">",
"      Miglior S, Zeyen T, Pfeiffer N, et al. Results of the European Glaucoma Prevention Study. Ophthalmology 2005; 112:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15289/abstract/25\">",
"      The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration.The AGIS Investigators. Am J Ophthalmol 2000; 130:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15289/abstract/26\">",
"      Mart&iacute;nez-Bell&oacute; C, Chauhan BC, Nicolela MT, et al. Intraocular pressure and progression of glaucomatous visual field loss. Am J Ophthalmol 2000; 129:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15289/abstract/27\">",
"      Bengtsson B, Leske MC, Hyman L, et al. Fluctuation of intraocular pressure and glaucoma progression in the early manifest glaucoma trial. Ophthalmology 2007; 114:205.",
"     </a>",
"    </li>",
"    <li>",
"     AAO, Preferred Practice Pattern, Primary Open-Angle Glaucoma, American Academy of Ophthalmology 1996.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15289/abstract/29\">",
"      Cedrone C, Mancino R, Cerulli A, et al. Epidemiology of primary glaucoma: prevalence, incidence, and blinding effects. Prog Brain Res 2008; 173:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15289/abstract/30\">",
"      Ellis JD, Evans JM, Ruta DA, et al. Glaucoma incidence in an unselected cohort of diabetic patients: is diabetes mellitus a risk factor for glaucoma? DARTS/MEMO collaboration. Diabetes Audit and Research in Tayside Study. Medicines Monitoring Unit. Br J Ophthalmol 2000; 84:1218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15289/abstract/31\">",
"      Girkin CA, McGwin G Jr, McNeal SF, et al. Hypothyroidism and the development of open-angle glaucoma in a male population. Ophthalmology 2004; 111:1649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15289/abstract/32\">",
"      Pasquale LR, Kang JH, Manson JE, et al. Prospective study of type 2 diabetes mellitus and risk of primary open-angle glaucoma in women. Ophthalmology 2006; 113:1081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15289/abstract/33\">",
"      Miglior S, Torri V, Zeyen T, et al. Intercurrent factors associated with the development of open-angle glaucoma in the European glaucoma prevention study. Am J Ophthalmol 2007; 144:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15289/abstract/34\">",
"      Xu L, Wang H, Wang Y, Jonas JB. Intraocular pressure correlated with arterial blood pressure: the beijing eye study. Am J Ophthalmol 2007; 144:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15289/abstract/35\">",
"      Gr&oslash;dum K, Heijl A, Bengtsson B. Risk of glaucoma in ocular hypertension with and without pseudoexfoliation. Ophthalmology 2005; 112:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15289/abstract/36\">",
"      Topouzis F, Harris A, Wilson MR, et al. Increased likelihood of glaucoma at the same screening intraocular pressure in subjects with pseudoexfoliation: the Thessaloniki Eye Study. Am J Ophthalmol 2009; 148:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15289/abstract/37\">",
"      Marcus MW, de Vries MM, Junoy Montolio FG, Jansonius NM. Myopia as a risk factor for open-angle glaucoma: a systematic review and meta-analysis. Ophthalmology 2011; 118:1989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15289/abstract/38\">",
"      J&uacute;lvez LP, Del Castillo S&aacute;nchez JB, Feijoo JG, Rubio-Terr&eacute;s C. Methodologic quality of studies on prognostic factors for primary open-angle glaucoma progression measured by visual field deterioration. J Glaucoma 2010; 19:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15289/abstract/39\">",
"      Susanna R Jr. Unpredictability of glaucoma progression. Curr Med Res Opin 2009; 25:2167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15289/abstract/40\">",
"      Kountouras J, Zavos C, Chatzopoulos D. Primary open-angle glaucoma: pathophysiology and treatment. Lancet 2004; 364:1311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15289/abstract/41\">",
"      Ray K, Mookherjee S. Molecular complexity of primary open angle glaucoma: current concepts. J Genet 2009; 88:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15289/abstract/42\">",
"      Wierzbowska J, Wierzbowski R, Stankiewicz A, et al. Cardiac autonomic dysfunction in patients with normal tension glaucoma: 24-h heart rate and blood pressure variability analysis. Br J Ophthalmol 2012; 96:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15289/abstract/43\">",
"      Heijl A, Bengtsson B, Hyman L, et al. Natural history of open-angle glaucoma. Ophthalmology 2009; 116:2271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15289/abstract/44\">",
"      Mowatt G, Burr JM, Cook JA, et al. Screening tests for detecting open-angle glaucoma: systematic review and meta-analysis. Invest Ophthalmol Vis Sci 2008; 49:5373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15289/abstract/45\">",
"      Maier PC, Funk J, Schwarzer G, et al. Treatment of ocular hypertension and open angle glaucoma: meta-analysis of randomised controlled trials. BMJ 2005; 331:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15289/abstract/46\">",
"      Epstein DL, Krug JH Jr, Hertzmark E, et al. A long-term clinical trial of timolol therapy versus no treatment in the management of glaucoma suspects. Ophthalmology 1989; 96:1460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15289/abstract/47\">",
"      Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002; 120:701.",
"     </a>",
"    </li>",
"    <li>",
"     Henderson P, Labbe T, Kass MA. Ocular Hypertension. In: Ophthalmology, Third, Yanoff M, Duker JS (Eds), Mosby Elsevier, 2009.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15289/abstract/49\">",
"      Tuulonen A. Cost-effectiveness of screening for open angle glaucoma in developed countries. Indian J Ophthalmol 2011; 59 Suppl:S24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15289/abstract/50\">",
"      Hern&aacute;ndez R, Rabindranath K, Fraser C, et al. Screening for open angle glaucoma: systematic review of cost-effectiveness studies. J Glaucoma 2008; 17:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15289/abstract/51\">",
"      Burr JM, Mowatt G, Hern&aacute;ndez R, et al. The clinical effectiveness and cost-effectiveness of screening for open angle glaucoma: a systematic review and economic evaluation. Health Technol Assess 2007; 11:iii.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15289/abstract/52\">",
"      Vaahtoranta-Lehtonen H, Tuulonen A, Aronen P, et al. Cost effectiveness and cost utility of an organized screening programme for glaucoma. Acta Ophthalmol Scand 2007; 85:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15289/abstract/53\">",
"      Hatt S, Wormald R, Burr J. Screening for prevention of optic nerve damage due to chronic open angle glaucoma. Cochrane Database Syst Rev 2006; :CD006129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15289/abstract/54\">",
"      U.S. Preventive Services Task Force. Screening for glaucoma: recommendation statement. Ann Fam Med 2005; 3:171.",
"     </a>",
"    </li>",
"    <li>",
"     Canadian Task Force on the Periodic Health Examination. Canadian guide to clinical preventive health care, Canada Communication Group, Ottawa 1994. p.932.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15289/abstract/56\">",
"      Wood CM, Bosanquet RC. Limitations of direct ophthalmoscopy in screening for glaucoma. Br Med J (Clin Res Ed) 1987; 294:1587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15289/abstract/57\">",
"      Zein WM, Bashshur ZF, Jaafar RF, Noureddin BN. The distribution of visual field defects per quadrant in standard automated perimetry as compared to frequency doubling technology perimetry. Int Ophthalmol 2010; 30:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15289/abstract/58\">",
"      Tielsch JM, Katz J, Singh K, et al. A population-based evaluation of glaucoma screening: the Baltimore Eye Survey. Am J Epidemiol 1991; 134:1102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15289/abstract/59\">",
"      Johnson CA, Keltner JL, Cello KE, et al. Baseline visual field characteristics in the ocular hypertension treatment study. Ophthalmology 2002; 109:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15289/abstract/60\">",
"      Ocular Hypertension Treatment Study Group and the European Glaucoma Prevention Study Group. The accuracy and clinical application of predictive models for primary open-angle glaucoma in ocular hypertensive individuals. Ophthalmology 2008; 115:2030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15289/abstract/61\">",
"      Harper R, Reeves B. The sensitivity and specificity of direct ophthalmoscopic optic disc assessment in screening for glaucoma: a multivariate analysis. Graefes Arch Clin Exp Ophthalmol 2000; 238:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15289/abstract/62\">",
"      Johnson LN, Baloh FG. The accuracy of confrontation visual field test in comparison with automated perimetry. J Natl Med Assoc 1991; 83:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15289/abstract/63\">",
"      Omoti AE, Okeigbemen VW, Waziri-Erameh JM. Current concepts in the diagnosis of primary open angle glaucoma. West Afr J Med 2009; 28:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15289/abstract/64\">",
"      Leske MC. The epidemiology of open-angle glaucoma: a review. Am J Epidemiol 1983; 118:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15289/abstract/65\">",
"      Armaly MF, Krueger DE, Maunder L, et al. Biostatistical analysis of the collaborative glaucoma study. I. Summary report of the risk factors for glaucomatous visual-field defects. Arch Ophthalmol 1980; 98:2163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15289/abstract/66\">",
"      Brandt JD, Beiser JA, Kass MA, Gordon MO. Central corneal thickness in the Ocular Hypertension Treatment Study (OHTS). Ophthalmology 2001; 108:1779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15289/abstract/67\">",
"      Teng C, Gurses-Ozden R, Liebmann JM, et al. Effect of a tight necktie on intraocular pressure. Br J Ophthalmol 2003; 87:946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15289/abstract/68\">",
"      European Glaucoma Prevention Study (EGPS) Group, Miglior S, Pfeiffer N, et al. Predictive factors for open-angle glaucoma among patients with ocular hypertension in the European Glaucoma Prevention Study. Ophthalmology 2007; 114:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15289/abstract/69\">",
"      Herndon LW, Weizer JS, Stinnett SS. Central corneal thickness as a risk factor for advanced glaucoma damage. Arch Ophthalmol 2004; 122:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15289/abstract/70\">",
"      Hazin R, Hendrick AM, Kahook MY. Primary open-angle glaucoma: diagnostic approaches and management. J Natl Med Assoc 2009; 101:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15289/abstract/71\">",
"      Li G, Fansi AK, Boivin JF, et al. Screening for glaucoma in high-risk populations using optical coherence tomography. Ophthalmology 2010; 117:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15289/abstract/72\">",
"      Badal&agrave; F, Nouri-Mahdavi K, Raoof DA, et al. Optic disk and nerve fiber layer imaging to detect glaucoma. Am J Ophthalmol 2007; 144:724.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6909 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.77.166.39-02DD474397-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_59_15289=[""].join("\n");
var outline_f14_59_15289=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H6892553\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H812842485\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H447095064\">",
"      SCREENING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1320774\">",
"      Evidence for treating elevated intraocular pressure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1320003\">",
"      Cost-effectiveness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H447095071\">",
"      Recommendations of others",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1930221\">",
"      Synthesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H387536684\">",
"      Who should be referred for comprehensive eye examination?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H447092864\">",
"      Diagnostic tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H387536783\">",
"      - Fundus examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Visual field testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Intraocular pressure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Pressure parameters for referral",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Pachymetry",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Newer technologies for fundus evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6892553\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/6909\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/6909|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/60/11201\" title=\"figure 1\">",
"      Angle anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/19/12595\" title=\"figure 2\">",
"      Open angle glaucoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?39/50/40738\" title=\"figure 3\">",
"      Angle-closure glaucoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?22/9/22680\" title=\"figure 4\">",
"      Glaucomatous visual field progression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/6909|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/54/29540\" title=\"picture 1A\">",
"      Assessment of optic disc A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/55/11127\" title=\"picture 1B\">",
"      Assessment of optic disc B",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?8/49/8979\" title=\"picture 2\">",
"      Applanation tonometry",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/54/9063?source=related_link\">",
"      Angle-closure glaucoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/12/17607?source=related_link\">",
"      Evaluation of the red eye",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/2/34855?source=related_link\">",
"      Open-angle glaucoma: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/31/41463?source=related_link\">",
"      Overview of glaucoma in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/35/11826?source=related_link\">",
"      Patient information: Age-related vision loss (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?2/13/2258?source=related_link\">",
"      Patient information: Glaucoma (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/57/5016?source=related_link\">",
"      Primary infantile glaucoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_59_15290="Diagnosis of monoclonal gammopathy of undetermined significance";
var content_f14_59_15290=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnosis of monoclonal gammopathy of undetermined significance",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/59/15290/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/59/15290/contributors\">",
"     S Vincent Rajkumar, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/59/15290/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/59/15290/contributors\">",
"     Robert A Kyle, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/59/15290/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/59/15290/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/59/15290/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 8, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Monoclonal gammopathy of undetermined significance (MGUS) is an asymptomatic premalignant clonal plasma cell or lymphoplasmacytic proliferative disorder. It is defined by the presence of a serum monoclonal protein (M-protein), at a concentration &lt;3",
"    <span class=\"nowrap\">",
"     g/dL,",
"    </span>",
"    and a bone marrow with &lt;10 percent monoclonal plasma cells, if done, and in the absence of end organ damage (lytic bone lesions, anemia, hypercalcemia, renal insufficiency, hyperviscosity) related to the proliferative process.",
"   </p>",
"   <p>",
"    MGUS occurs in over 3 percent of the general Caucasian population over the age of 50 and is typically detected as an incidental finding when patients undergo a protein electrophoresis as part of an evaluation for a wide variety of clinical symptoms and disorders (eg, peripheral neuropathy, vasculitis, hemolytic anemia, skin rashes, hypercalcemia, or elevated erythrocyte sedimentation rate).",
"   </p>",
"   <p>",
"    There are three distinct clinical types of MGUS, each with a risk of progressing through a unique intermediate (more advanced) premalignant stage and then to a malignant plasma cell dyscrasia or lymphoproliferative disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15290/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Non-IgM MGUS (IgG, IgA, or IgD MGUS) &mdash; Non-IgM MGUS is the most common subtype of MGUS and has the potential to progress to smoldering (asymptomatic) multiple myeloma and to symptomatic multiple myeloma. Less frequently, these patients progress to AL amyloidosis, light chain deposition disease, or another lymphoproliferative disorder.",
"     </li>",
"     <li>",
"      IgM MGUS &mdash; IgM MGUS accounts for approximately 15 percent of MGUS cases. It is considered separately from the non-IgM MGUS because it has the potential to progress to smoldering Waldenstrom macroglobulinemia and to symptomatic Waldenstrom macroglobulinemia and less often to lymphoma or AL amyloidosis. Infrequently, IgM MGUS can progress to IgM multiple myeloma.",
"     </li>",
"     <li>",
"      Light chain MGUS (LC-MGUS) &mdash; LC-MGUS is a unique subtype of MGUS in which the secreted monoclonal protein lacks the immunoglobulin heavy chain component. LC-MGUS may progress to idiopathic Bence Jones proteinuria and to light chain multiple myeloma, AL amyloidosis, or light chain deposition disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The generic term MGUS used in most studies only includes patients with non-IgM MGUS and IgM MGUS; LC-MGUS is a newly defined entity. The diagnosis of patients with MGUS will be discussed here [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15290/abstract/2-5\">",
"     2-5",
"    </a>",
"    ]. The management of patients with MGUS, the recognition of serum or urinary monoclonal proteins, and a discussion of the clinical features, laboratory manifestations, and diagnosis of multiple myeloma and other plasma cell dyscrasias are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/60/4041?source=see_link\">",
"     \"Clinical course and management of monoclonal gammopathy of undetermined significance\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/58/10154?source=see_link\">",
"     \"Recognition of monoclonal proteins\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/13/35034?source=see_link\">",
"     \"Clinical features, laboratory manifestations, and diagnosis of multiple myeloma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/47/762?source=see_link\">",
"     \"Epidemiology, pathogenesis, clinical manifestations and diagnosis of Waldenstr&ouml;m macroglobulinemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/62/35815?source=see_link\">",
"     \"Pathogenesis of immunoglobulin light chain (AL) amyloidosis and light and heavy chain deposition diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;MGUS was found in approximately 1 to 2 percent of adults in studies from Sweden, the United States, France, and Japan [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15290/abstract/6-10\">",
"     6-10",
"    </a>",
"    ]. The mean age at diagnosis is 70 years and less than 2 percent of patients are diagnosed before the age of 40 [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15290/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. The incidence and prevalence rises with patient age [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15290/abstract/11,13,14\">",
"     11,13,14",
"    </a>",
"    ], is higher in men than women [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15290/abstract/11\">",
"     11",
"    </a>",
"    ], and is two- to threefold higher in Africans and African-Americans compared with Caucasians [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15290/abstract/15-18\">",
"     15-18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The incidence of MGUS in men is estimated to be 120 per 100,000 at age 50 and increases to 530 per 100,000 by the age of 90. The corresponding rates for women are 60 per 100,000 population at age 50, and 370 per 100,000 at age 90 [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15290/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The best estimates of prevalence come from population-based studies of a geographically defined area during a specific time period. Factors that influence the findings of such studies include demographic features of the screened population (ie, age, sex, race), the presence of risk factors for MGUS in the population (eg, occupational and environmental risk factors, immune status, and familial risk), and logistical features of the study (eg, how the study identified populations to screen, the sensitivity of the diagnostic tests used, and the diagnostic criteria used) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15290/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prevalence of MGUS among a well-defined, largely Caucasian population was determined by agarose gel electrophoresis followed by immunofixation in 21,463 of the 28,038 enumerated residents (77 percent) of Olmsted County, Minnesota who were &ge;50 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15290/abstract/11\">",
"     11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The prevalence of MGUS in persons &ge;50, &ge;70, and &ge;85 years of age was 3.2, 5.3, and 7.5 percent, respectively.",
"     </li>",
"     <li>",
"      Age-adjusted rates for persons &ge;50 were significantly higher in men than in women (4.0 versus 2.7 percent).",
"     </li>",
"     <li>",
"      Further evaluation noted the prevalence of light chain-MGUS and MGUS in persons over age 50 was 0.8 and 3.4 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?14/59/15290/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Many studies have demonstrated the effects of race on MGUS frequency. A study from Ghana used stratified random sampling to estimate the incidence of MGUS in black men from western Africa at twice that of the white population from Minnesota [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15290/abstract/18\">",
"     18",
"    </a>",
"    ]. A two- to threefold higher frequency in MGUS among American blacks was also seen in a large study of inpatients from US Veterans Affairs hospitals [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15290/abstract/17\">",
"     17",
"    </a>",
"    ] and a large population-based study of Southern women [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15290/abstract/21\">",
"     21",
"    </a>",
"    ]. The latter study also showed that the increased risk of MGUS seen in African-Americans persists in a cohort of women of similar socio-economic status. These and other studies suggest that the racial predisposition to MGUS and MM observed in blacks is likely related to shared genetics, rather than environmental factors [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15290/abstract/18,21\">",
"     18,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is a paucity of information regarding the incidence in other races. A study in adult Asians from Japan that used an older method for screening suggests that Japanese persons may have a slightly lower incidence than that seen in Caucasians from Minnesota [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15290/abstract/10\">",
"     10",
"    </a>",
"    ]. The limited data available also suggest that the prevalence of MGUS in Mexicans is less than in Caucasians from Minnesota [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15290/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Family studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;While most cases of MGUS appear to be sporadic, relatives of persons with MGUS have an increased risk of developing MGUS and related diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15290/abstract/23\">",
"     23",
"    </a>",
"    ]. Studies of the incidence of plasma cell and lymphoproliferative disorders among first-degree relatives of patients with multiple myeloma or MGUS support a shared environmental",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    genetic predisposition to these disorders.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Using population-based data from Sweden, relatives of MGUS patients had significantly increased risks for MGUS (relative risk, RR 2.8), multiple myeloma (RR 2.9), lymphoplasmacytic",
"      <span class=\"nowrap\">",
"       lymphoma/Waldenstrom",
"      </span>",
"      macroglobulinemia (RR 4.0), and chronic lymphocytic leukemia (RR 2.0) [",
"      <a class=\"abstract\" href=\"UTD.htm?14/59/15290/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Using a cohort of MGUS patients from Olmsted County identified through a population-based prevalence study and patients with myeloma or MGUS from the Mayo Clinic, the risk of MGUS was found to be significantly increased among relatives of those with myeloma (RR 2.0) or MGUS (RR 3.3) [",
"      <a class=\"abstract\" href=\"UTD.htm?14/59/15290/abstract/25,26\">",
"       25,26",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Since there are no proven preventative approaches, there is no role for screening asymptomatic relatives at this time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H90176672\">",
"    <span class=\"h2\">",
"     Associated conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;MGUS has been reported in association with several non-malignant disorders, some of them quite rare (",
"    <a class=\"graphic graphic_table graphicRef70820 \" href=\"UTD.htm?43/21/44380\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15290/abstract/27\">",
"     27",
"    </a>",
"    ], and also has been reported along with autoimmune disorders, such as systemic lupus erythematosus and immune thrombocytopenia (ITP) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15290/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. It is not clear whether these conditions are pathogenetically related or merely represent coincidental associations, given the relatively frequent occurrence of MGUS in the general population above the age of 50.",
"   </p>",
"   <p>",
"    A population-based study of 17,398 subjects from Olmsted County found a number of previously unreported disease associations with MGUS, including mycobacterial infection and superficial thrombophlebitis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15290/abstract/30\">",
"     30",
"    </a>",
"    ]. An appendix providing the incidence of each of the 16,062 disease codes in patients with MGUS and controls, along with relative risks and confidence intervals is available at",
"    <a class=\"external\" href=\"file://www.mayoclinicproceedings.com/content/84/8/685/suppl/DC1\">",
"     the Mayo Clinic Proceedings website",
"    </a>",
"    . There is also an increased risk of fractures in patients with MGUS compared with the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15290/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Rare cases of telangiectasias, erythrocytosis with elevated erythropoietin, MGUS, perinephric fluid collections, and intrapulmonary shunting (TEMPI syndrome) have been reported in the literature although little is known about the physiological basis of this constellation of symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15290/abstract/32-34\">",
"     32-34",
"    </a>",
"    ]. Responses have been reported after administration of the proteosome inhibitor",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    , suggesting that these symptoms are at least partially related to the underlying plasma cell dyscrasia [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15290/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Of importance, MGUS has been described in approximately one-third of patients with acquired angioedema (acquired C1 inhibitor deficiency). Laryngeal edema is the most severe and potentially lethal complication of acquired angioedema, which may require urgent treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/57/23444?source=see_link\">",
"     C1 inhibitor concentrate",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/12/26824?source=see_link\">",
"     \"Acquired C1 inhibitor deficiency: Clinical manifestations, epidemiology, pathogenesis, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/20/25927?source=see_link\">",
"     \"Acquired C1 inhibitor deficiency: Management and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H90177415\">",
"    <span class=\"h1\">",
"     PRESENTING FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;By definition, patients with MGUS have no symptoms of myeloma or related malignancy that can be attributable to their monoclonal protein. Most patients are identified when a monoclonal protein is detected as an incidental finding on protein electrophoresis performed as part of an evaluation for one of a wide variety of clinical symptoms and disorders (eg, peripheral neuropathy, vasculitis, hemolytic anemia, skin rashes, hypercalcemia, elevated erythrocyte sedimentation rate).",
"   </p>",
"   <p>",
"    Since MGUS is asymptomatic, the condition is likely to have existed in an undetected state for years prior to diagnosis. As an example, a population-based prevalence study of 21,463 persons from Olmsted County, Minnesota estimated that more than half of men and women diagnosed with MGUS at age 70 years had had a monoclonal protein for at least 10 years, and that approximately one-quarter had had a monoclonal protein for 20 years [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15290/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H90177423\">",
"    <span class=\"h2\">",
"     Monoclonal proteins",
"    </span>",
"    &nbsp;&mdash;&nbsp;MGUS (non-IgM and IgM) is characterized by the presence of a monoclonal (M) protein produced and secreted by clonal plasma cells, which can be detected by protein electrophoresis of the serum (SPEP)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    of an aliquot of urine (UPEP) from a 24-hour collection combined with immunofixation of the serum and urine. Serum free light chain assays can detect low concentrations of monoclonal free light chain in the serum. They can be used to diagnose light-chain MGUS and predict the risk of progression of MGUS. &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/58/10154?source=see_link&amp;anchor=H2212935#H2212935\">",
"     \"Recognition of monoclonal proteins\", section on 'Indications and uses'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The M-protein usually presents as a single narrow peak, like a church spire, in the gamma, beta, or alpha-2 region of the densitometer tracing (",
"    <a class=\"graphic graphic_figure graphicRef67685 \" href=\"UTD.htm?21/3/21566\">",
"     figure 1",
"    </a>",
"    ) or as a dense, discrete band on the agarose gel (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef62500 \" href=\"UTD.htm?6/58/7087\">",
"     image 1",
"    </a>",
"    ). Two M proteins are present (biclonal gammopathy) in 2 to 4 percent (",
"    <a class=\"graphic graphic_figure graphicRef54186 \" href=\"UTD.htm?29/1/29727\">",
"     figure 2",
"    </a>",
"    ) of patients with clonal plasma cell disorders. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/58/10154?source=see_link\">",
"     \"Recognition of monoclonal proteins\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Serum immunofixation confirms the presence of an M-protein and determines its type (",
"    <a class=\"graphic graphic_figure graphicRef55916 \" href=\"UTD.htm?4/39/4735\">",
"     figure 3",
"    </a>",
"    ). The clonal plasma cells can produce immunoglobulin heavy chains plus light chains or light chains alone, with the following frequencies (",
"    <a class=\"graphic graphic_table graphicRef73099 \" href=\"UTD.htm?14/17/14620\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15290/abstract/11,36\">",
"     11,36",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      IgG &mdash; 69 percent",
"     </li>",
"     <li>",
"      IgM &mdash; 17 percent",
"     </li>",
"     <li>",
"      IgA &mdash; 11 percent",
"     </li>",
"     <li>",
"      IgD &mdash; &lt;1 percent",
"     </li>",
"     <li>",
"      Biclonal &mdash; 3 percent",
"     </li>",
"     <li>",
"      Kappa light chain &mdash; 62 percent",
"     </li>",
"     <li>",
"      Lambda light chain &mdash; 38 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The presence of an IgD M-protein almost always indicates multiple myeloma, AL amyloid, or plasma cell leukemia, although two cases of IgD MGUS have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15290/abstract/2\">",
"     2",
"    </a>",
"    ]. Of the approximately 0.8 percent of the population age &ge;50 that have light chain-MGUS, 74 percent have a kappa light-chain predominance [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15290/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The amount of monoclonal protein in MGUS is usually small and by definition less than 3",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    in the serum. In a large population-based study, the concentration of monoclonal immunoglobulin was &lt;1.0",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    in 63.5 percent, and &ge;2.0",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    in 4.5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15290/abstract/11\">",
"     11",
"    </a>",
"    ]. Approximately one-third of patients will have a decrease in the concentration of uninvolved immunoglobulins (eg, IgM and IgA in the case of IgG MGUS) and many demonstrate a reduction in normal polyclonal or background immunoglobulins [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15290/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. A monoclonal urinary light chain is seen in approximately 20 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H90179087\">",
"    <span class=\"h2\">",
"     Biclonal gammopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, 3 percent of patients with MGUS had biclonal, rather than monoclonal, gammopathy. Such patients have the same clinical spectrum as those with monoclonal gammopathy, and should be followed in the same manner [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15290/abstract/39\">",
"     39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/58/10154?source=see_link&amp;anchor=H1965968#H1965968\">",
"     \"Recognition of monoclonal proteins\", section on 'Biclonal gammopathy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H90177451\">",
"    <span class=\"h2\">",
"     Laboratory artifacts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Circulating monoclonal proteins may interfere with one or more laboratory tests performed on liquid-based automated analyzers, either by precipitating during the analysis, or by virtue of their specific binding properties. The most common artifacts are a low value for HDL cholesterol, a high value for bilirubin, as well as altered measurement of inorganic phosphate. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/58/10154?source=see_link&amp;anchor=H5#H5\">",
"     \"Recognition of monoclonal proteins\", section on 'Interference with laboratory tests'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although not a laboratory artifact, monoclonal protein can increase the serum viscosity and erythrocyte sedimentation rate (ESR).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H90177465\">",
"    <span class=\"h2\">",
"     Peripheral smear",
"    </span>",
"    &nbsp;&mdash;&nbsp;The complete blood count and peripheral smear are usually normal. Infrequently, rouleaux formation is seen. Rouleaux formation is the phenomenon in which red cells take on the appearance of a stack of coins in diluted suspensions of blood, and is seen in patients with elevated serum protein levels (",
"    <a class=\"graphic graphic_picture graphicRef74369 \" href=\"UTD.htm?27/33/28183\">",
"     picture 1",
"    </a>",
"    ). The presence of circulating plasma cells of the same isotype in the peripheral blood, as detected using a slide-based immunofluorescence assay or flow cytometry, is more commonly seen with active MM, but can also be seen in some patients with MGUS [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15290/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/26/38313?source=see_link&amp;anchor=H2#H2\">",
"     \"Evaluation of the peripheral blood smear\", section on 'Initial approach'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H90177472\">",
"    <span class=\"h2\">",
"     Bone marrow examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;A bone marrow aspirate and biopsy must demonstrate fewer than 10 percent clonal plasma cells, or in the case of IgM MGUS, fewer than 10 percent infiltration by clonal lymphoplasmacytic cells. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/13/35034?source=see_link&amp;anchor=H18#H18\">",
"     \"Clinical features, laboratory manifestations, and diagnosis of multiple myeloma\", section on 'Bone marrow examination'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/61/38872?source=see_link&amp;anchor=H9#H9\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of lymphoplasmacytic lymphoma\", section on 'Bone marrow'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Conventional cytogenetics are normal in patients with MGUS because of the low proliferative rate and small number of plasma cells within the bone marrow samples. However, studies using more sensitive methods have shown that chromosomal abnormalities are very common in MGUS [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15290/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Results obtained by interphase FISH demonstrate chromosomal aneuploidy (especially hyperdiploidy) in approximately 50 percent of patients with MGUS [",
"      <a class=\"abstract\" href=\"UTD.htm?14/59/15290/abstract/43-45\">",
"       43-45",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Translocations affecting the immunoglobulin heavy-chain (IgH) locus on chromosome 14q32 and five key partner chromosomes have been observed in the remaining 50 percent of patients with MGUS. These include: t(11;14) affecting the cyclin D1 gene, t(4;14) affecting the FGFR-3 and MMSET genes, t(6;14) affecting the cyclin D3 gene, t(14;16) affecting the cmaf gene and t(14;20) affecting the mafB gene [",
"      <a class=\"abstract\" href=\"UTD.htm?14/59/15290/abstract/46,47\">",
"       46,47",
"      </a>",
"      ]. These five translocations are termed \"primary\" IgH translocations. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/20/27977?source=see_link&amp;anchor=H7#H7\">",
"       \"Pathobiology of multiple myeloma\", section on 'Immunoglobulin heavy chain translocations'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Chromosomal abnormalities detected by FISH, including hyperdiploidy, IgH translocations, and deletion of chromosome 13 are not used to differentiate MGUS from multiple myeloma (MM). The specific abnormalities that might indicate a high rate of progression from MGUS to MM have not yet been reliably identified [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15290/abstract/42,44,48\">",
"     42,44,48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H282159971\">",
"    <span class=\"h2\">",
"     Screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no role for screening of asymptomatic patients of any age for monoclonal gammopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15290/abstract/49\">",
"     49",
"    </a>",
"    ]. Such screening would be associated with high costs for payers and undue emotional burden on persons with a low risk of progressing to a symptomatic disorder. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/60/4041?source=see_link&amp;anchor=H22391006#H22391006\">",
"     \"Clinical course and management of monoclonal gammopathy of undetermined significance\", section on 'Disease progression'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H90175591\">",
"    <span class=\"h2\">",
"     Evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of MGUS is usually incidental when a monoclonal protein &lt;3",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    is found as part of the evaluation of another disorder, such as unexplained age-inappropriate bone loss, unexplained proteinuria, an elevated total protein in the blood, or peripheral neuropathy without a defined etiology [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15290/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At a minimum, patients suspected of having MGUS should be evaluated with the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Complete blood count",
"     </li>",
"     <li>",
"      Serum calcium and creatinine",
"     </li>",
"     <li>",
"      Serum protein electrophoresis and immunofixation",
"     </li>",
"     <li>",
"      Urine protein electrophoresis and immunofixation",
"     </li>",
"     <li>",
"      Serum free light chain assay",
"     </li>",
"     <li>",
"      Quantitation of immunoglobulins",
"     </li>",
"     <li>",
"      Metastatic bone survey in patients with intermediate or high-risk MGUS and in any patient where there is a concern for myeloma (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/60/4041?source=see_link&amp;anchor=H22391048#H22391048\">",
"       \"Clinical course and management of monoclonal gammopathy of undetermined significance\", section on 'Risk stratification'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Evaluation of the urine is usually performed using routine urinalysis and 24-hour urine collection with electrophoresis and immunofixation. Routine dipstick of the urine for protein is not sufficient. The dipstick primarily detects albumin, the excretion of which is typically increased in renal amyloidosis, but the dipstick test often does not detect immunoglobulin light chains. Alternatively, one could perform protein electrophoresis and immunofixation on a single voided urine specimen. A 24-hour collection to quantitate urinary protein excretion would be necessary only if the \"spot test\" result is positive. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/37/13914?source=see_link&amp;anchor=H6#H6\">",
"     \"Assessment of urinary protein excretion and evaluation of isolated non-nephrotic proteinuria in adults\", section on 'Detection and measurement of total urinary protein excretion'",
"    </a>",
"    and",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?20/41/21151?source=see_link\">",
"     \"Patient information: Collection of a 24-hour urine specimen (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A bone marrow aspiration and biopsy is indicated in all patients with an M protein &ge;1.5",
"    <span class=\"nowrap\">",
"     g/dL,",
"    </span>",
"    patients with a non-IgG MGUS, patients with an abnormal serum free light chain ratio (ie, ratio of kappa to lambda free light chains &lt;0.26 or &gt;1.65), and in all patients who have any abnormalities of the CBC, serum creatinine, serum calcium, or radiographic bone survey. A bone marrow may be considered in all other patients with MGUS, but can be deferred in older asymptomatic adults or in frail older adults with limited life expectancy in whom myeloma or a related malignancy is considered unlikely, who can be safely followed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/60/4041?source=see_link&amp;anchor=H22391048#H22391048\">",
"     \"Clinical course and management of monoclonal gammopathy of undetermined significance\", section on 'Risk stratification'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Computerized tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography (PET) are more sensitive than plain radiographs at detecting bone involvement by multiple myeloma; however, the clinical importance of asymptomatic bone lesions detected by these imaging modalities alone is not clear. For patients with non-IgM MGUS, we reserve CT, MRI, and",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    for select patients such as those with bone pain without an abnormality on skeletal survey [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15290/abstract/50\">",
"     50",
"    </a>",
"    ]. Patients with an IgM monoclonal protein should have a CT scan of the chest and abdomen because asymptomatic lymph node enlargement may be present [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15290/abstract/3\">",
"     3",
"    </a>",
"    ]. Lymphadenopathy in the setting of an IgM monoclonal protein is suggestive of Waldenstrom macroglobulinemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/47/762?source=see_link&amp;anchor=H21#H21\">",
"     \"Epidemiology, pathogenesis, clinical manifestations and diagnosis of Waldenstr&ouml;m macroglobulinemia\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H90176110\">",
"    <span class=\"h2\">",
"     Diagnostic criteria",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H90176118\">",
"    <span class=\"h3\">",
"     Non-IgM MGUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Non-IgM MGUS (IgG, IgA, or IgD MGUS) is diagnosed by meeting the following three criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15290/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The presence of a serum monoclonal protein (M-protein, whether IgA, IgG, or IgD), at a concentration &lt;3",
"      <span class=\"nowrap\">",
"       g/dL.",
"      </span>",
"      The M-protein is detected with serum protein electrophoresis followed by immunofixation for the identification of the M-protein type (",
"      <a class=\"graphic graphic_figure graphicRef67685 \" href=\"UTD.htm?21/3/21566\">",
"       figure 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef55916 \" href=\"UTD.htm?4/39/4735\">",
"       figure 3",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?14/59/15290/abstract/53\">",
"       53",
"      </a>",
"      ]. It must be distinguished from a polyclonal gammopathy (",
"      <a class=\"graphic graphic_figure graphicRef74708 \" href=\"UTD.htm?18/4/18510\">",
"       figure 4",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/58/10154?source=see_link\">",
"       \"Recognition of monoclonal proteins\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Fewer than 10 percent clonal plasma cells in the bone marrow.",
"     </li>",
"     <li>",
"      The absence of lytic bone lesions, anemia, hypercalcemia, and renal insufficiency related to the plasma cell proliferative process. A skeletal survey is adequate to assess the presence of bone lesions if MGUS is suspected. However, if other imaging studies (such as an MRI, CT, or",
"      <span class=\"nowrap\">",
"       PET/CT)",
"      </span>",
"      are done, they should demonstrate no evidence of bone lesions that can be attributed to the plasma cell disorder.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H174976281\">",
"    <span class=\"h3\">",
"     IgM MGUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;IgM MGUS is diagnosed by meeting the following three criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15290/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The presence of a serum IgM monoclonal protein at a concentration &lt;3",
"      <span class=\"nowrap\">",
"       g/dL.",
"      </span>",
"      The M-protein is detected with serum protein electrophoresis followed by immunofixation for the identification of the M-protein type (",
"      <a class=\"graphic graphic_figure graphicRef67685 \" href=\"UTD.htm?21/3/21566\">",
"       figure 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef55916 \" href=\"UTD.htm?4/39/4735\">",
"       figure 3",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?14/59/15290/abstract/53\">",
"       53",
"      </a>",
"      ]. It must be distinguished from a polyclonal gammopathy (",
"      <a class=\"graphic graphic_figure graphicRef74708 \" href=\"UTD.htm?18/4/18510\">",
"       figure 4",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/58/10154?source=see_link\">",
"       \"Recognition of monoclonal proteins\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Fewer than 10 percent clonal lymphoplasmacytic cells in the bone marrow.",
"     </li>",
"     <li>",
"      The absence of end-organ damage such as anemia, constitutional symptoms, hyperviscosity, lymphadenopathy, or hepatosplenomegaly related to the plasma cell proliferative process. These patients must then be followed [",
"      <a class=\"abstract\" href=\"UTD.htm?14/59/15290/abstract/54\">",
"       54",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/47/762?source=see_link&amp;anchor=H5#H5\">",
"       \"Epidemiology, pathogenesis, clinical manifestations and diagnosis of Waldenstr&ouml;m macroglobulinemia\", section on 'Clinical presentation'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H90176125\">",
"    <span class=\"h3\">",
"     Light-chain MGUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Light-chain MGUS (LC-MGUS) is diagnosed by meeting the following three criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15290/abstract/20\">",
"     20",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The presence of an abnormal free light-chain ratio (ie, ratio of kappa to lambda free light chains &lt;0.26 or &gt;1.65)",
"     </li>",
"     <li>",
"      Increased level of the appropriate involved light chain (eg, increased kappa FLC in patients with a ratio &gt;1.65 and increased lambda FLC in patients with a ratio &lt;0.26)",
"     </li>",
"     <li>",
"      No monoclonal immunoglobulin heavy chain (IgG, IgA, IgD, or IgM)",
"     </li>",
"     <li>",
"      Fewer than 10 percent clonal lymphoplasmacytic cells in the bone marrow",
"     </li>",
"     <li>",
"      The absence of lytic bone lesions, anemia, hypercalcemia, and renal insufficiency related to the plasma cell proliferative process. A skeletal survey is adequate to assess the presence of bone lesions if MGUS is suspected. However, if other imaging studies (such as an MRI, CT, or",
"      <span class=\"nowrap\">",
"       PET/CT)",
"      </span>",
"      are done, they should demonstrate no evidence of bone lesions that can be attributed to the plasma cell disorder.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Subjects with an abnormal free light-chain ratio and no expression of an immunoglobulin heavy chain, but without an increased concentration of the involved light chain are not considered to have LC-MGUS. Instead, abnormal free light-chain ratios in these persons likely reflect renal dysfunction or polyclonal activation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/58/10154?source=see_link&amp;anchor=H2212942#H2212942\">",
"     \"Recognition of monoclonal proteins\", section on 'Use in patients with renal insufficiency'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is important to distinguish MGUS from more advanced plasma cell dyscrasias for the purposes of prognosis and treatment. The main conditions to consider in the differential diagnosis of MGUS are multiple myeloma (smoldering or symptomatic), Waldenstrom macroglobulinemia (smoldering or symptomatic), idiopathic Bence Jones proteinuria, and primary amyloidosis (AL) (",
"    <a class=\"graphic graphic_table graphicRef67431 \" href=\"UTD.htm?11/46/12014\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Multiple myeloma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both MGUS and multiple myeloma (MM) are characterized by a monoclonal protein in the serum (IgG, IgA, or IgD; kappa or lambda) or in the urine (kappa or lambda) that is produced by a clonal population of plasma cells in the bone marrow. A subset of patients with MGUS will progress to smoldering (asymptomatic) multiple myeloma and then to symptomatic MM. It is impossible to differentiate MGUS from those who subsequently develop smoldering or symptomatic MM at the time of initial presentation.",
"   </p>",
"   <p>",
"    By definition, any patient with a non IgM serum monoclonal protein &ge;3",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    or with &ge;10 percent clonal plasma cells in the bone marrow does",
"    <strong>",
"     not",
"    </strong>",
"    have MGUS. In such a case, a diagnosis of MM or smoldering MM (SMM) should be made based upon the presence or absence of symptoms. The morphologic appearance of the plasma cells in the bone marrow is of little help unless the cells have plasmablastic morphologic features (eg, nucleoli), which favors the diagnosis of MM [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15290/abstract/55\">",
"     55",
"    </a>",
"    ]. However, due to patchy bone marrow involvement, approximately 4 percent of patients with MM will have a bone marrow aspirate and biopsy demonstrating less than 10 percent clonal plasma cells [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15290/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While the diagnosis of MGUS requires the absence of anemia, hypercalcemia, renal failure, and lytic bone lesions related to the plasma cell proliferative disorder, the mere presence of one or more of these features in conjunction with an M protein does not automatically indicate MM or related malignancy, since these abnormalities may be due to unrelated coexisting diseases. As an example, patients with MGUS may have anemia related to nutritional deficiency; renal failure related to coexisting diabetes or hypertension; hypercalcemia due to hyperparathyroidism; or lytic bone lesions from metastatic carcinoma. Only patients in whom these clinical findings of end organ damage are felt to be clearly related to the plasma cell disorder are considered to have MM. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/13/35034?source=see_link\">",
"     \"Clinical features, laboratory manifestations, and diagnosis of multiple myeloma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The presence of osteolytic lesions and unexplained hypercalcemia strongly suggests MM, but metastatic carcinoma must be excluded.",
"     </li>",
"     <li>",
"      MRI of the skull, spine, and pelvis may be of value in distinguishing between MGUS and overt MM in patients with symptomatic bone disease and a normal radiographic bone survey. In one series, MRI was normal in patients with MGUS and abnormal in more than 80 percent of those with overt MM [",
"      <a class=\"abstract\" href=\"UTD.htm?14/59/15290/abstract/57\">",
"       57",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Similarly, unexplained renal insufficiency suggests possible involvement by the light chains due to MGUS, MM or a related malignancy. If renal dysfunction is not accompanied by significant light chain excretion or other features of MM, a renal biopsy may be needed to ascertain that the renal failure is caused by the plasma cell proliferative process [",
"      <a class=\"abstract\" href=\"UTD.htm?14/59/15290/abstract/58\">",
"       58",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/11/21690?source=see_link\">",
"       \"Indications for and complications of renal biopsy\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H2549497\">",
"       'Monoclonal gammopathy of renal significance'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other laboratory determinations, such as a low CD4 cell count, chromosomal abnormalities with FISH analysis (eg, deletion 13), the presence of J chains in plasma cells, and elevated plasma cell acid phosphatase levels are all unreliable for differentiation of MGUS and multiple myeloma. More sophisticated techniques of differentiating MGUS from MM (eg, plasma cell labeling index, serum concentration of interleukin-6, gene expression profiling) are not used in routine clinical practice [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15290/abstract/40,41,59-63\">",
"     40,41,59-63",
"    </a>",
"    ]. However, a clearly elevated level of beta-2 microglobulin in the absence of renal failure",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    an inflammatory process would suggest a diagnosis of MM, and the patient should be carefully evaluated for this possibility.",
"   </p>",
"   <p>",
"    If there are doubts about the differentiation of MGUS and SMM from myeloma, and whether to begin chemotherapy immediately, one should withhold treatment and re-evaluate in two or three months. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/29/8666?source=see_link\">",
"     \"Determination of initial therapy in patients with multiple myeloma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H90179596\">",
"    <span class=\"h3\">",
"     Smoldering multiple myeloma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Smoldering multiple myeloma (SMM), also called asymptomatic multiple myeloma, is an intermediate stage between MGUS and symptomatic multiple myeloma. SMM is diagnosed in persons who meet the following criteria (",
"    <a class=\"graphic graphic_table graphicRef57627 \" href=\"UTD.htm?41/38/42603\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15290/abstract/52,64,65\">",
"     52,64,65",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Serum monoclonal protein &ge;3",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      &ge;10 to &lt;60 percent bone marrow clonal plasma cells",
"     </li>",
"     <li>",
"      Absence of lytic lesions, anemia, hypercalcemia, and renal insufficiency (end-organ damage) attributable to the underlying plasma cell proliferation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    SMM is distinguished from MGUS based on the size of the M protein and the percent plasma cells in the bone marrow. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/13/35034?source=see_link&amp;anchor=H30#H30\">",
"     \"Clinical features, laboratory manifestations, and diagnosis of multiple myeloma\", section on 'Smoldering multiple myeloma'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    SMM is distinguished from multiple myeloma based on the absence or presence of end-organ damage (hypercalcemia, anemia, bone lesions, renal failure) that is thought to be related to the underlying plasma cell disorder.",
"   </p>",
"   <p>",
"    Patients with SMM should have less than 60 percent bone marrow clonal plasma cells. Patients who have 60 percent or more clonal bone marrow plasma cells rarely present without end-organ damage attributable to the plasma cell disorder, and even if they do present as such, they almost inevitably progress to overt multiple myeloma within two years (median time to progression is seven months) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15290/abstract/66\">",
"     66",
"    </a>",
"    ]. Therefore, such patients are best considered as having multiple myeloma even in the absence of end-organ damage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H62135187\">",
"    <span class=\"h3\">",
"     Secondary MGUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Secondary MGUS refers to the development of a new monoclonal protein during the course of multiple myeloma that has an isotype (heavy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    light chain) distinct from the original clone (eg, IgM MGUS in a patient with IgG multiple myeloma). In a series of 1942 patients with multiple myeloma, secondary MGUS developed in 128 (6.6 percent) at a median of 12 months from the diagnosis of myeloma [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15290/abstract/67\">",
"     67",
"    </a>",
"    ]. More than one isotype occurred in approximately 30 percent of patients. Secondary MGUS was more common among patients who had undergone hematopoietic cell transplantation and was associated with superior survival. The MGUS commonly resolved without treatment with a median duration of approximately six months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H90179678\">",
"    <span class=\"h2\">",
"     Waldenstrom macroglobulinemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Waldenstrom macroglobulinemia (WM) is a distinct clinicopathologic entity demonstrating lymphoplasmacytic lymphoma (LPL) in the bone marrow with an IgM monoclonal gammopathy in the blood. Unlike patients with IgM MGUS who are asymptomatic, patients with WM may present with symptoms related to the infiltration of the hematopoietic tissues or the effects of monoclonal IgM in the blood. Symptoms of hyperviscosity and the presence of lymphadenopathy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    splenomegaly favor a diagnosis of WM. There is a greater probability of an abnormal free light chain ratio in Waldenstrom macroglobulinemia compared with IgM MGUS. In one study, an abnormal",
"    <span class=\"nowrap\">",
"     kappa/lambda",
"    </span>",
"    serum free light chain ratio was found in 76 and 24 percent of those with WM and IgM MGUS, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15290/abstract/68\">",
"     68",
"    </a>",
"    ]. Smoldering WM is considered an intermediate entity between IgM MGUS and WM, which fits the diagnostic criteria for WM but has not yet resulted in symptoms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/47/762?source=see_link\">",
"     \"Epidemiology, pathogenesis, clinical manifestations and diagnosis of Waldenstr&ouml;m macroglobulinemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    To make a diagnosis of WM (smoldering or symptomatic), the following criteria must be met [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15290/abstract/69\">",
"     69",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      An IgM monoclonal gammopathy (of any size) must be present in the serum.",
"     </li>",
"     <li>",
"      Ten percent or more of the bone marrow biopsy sample must demonstrate infiltration by LPL.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients without end-organ damage such as anemia, constitutional symptoms, hyperviscosity, lymphadenopathy, or hepatosplenomegaly related to the plasma cell proliferative process must be followed closely [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15290/abstract/54\">",
"     54",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/47/762?source=see_link&amp;anchor=H5#H5\">",
"     \"Epidemiology, pathogenesis, clinical manifestations and diagnosis of Waldenstr&ouml;m macroglobulinemia\", section on 'Clinical presentation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2549497\">",
"    <span class=\"h2\">",
"     Monoclonal gammopathy of renal significance",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term &ldquo;monoclonal gammopathy of renal significance&rdquo; (MGRS) has been proposed by the International Kidney and Monoclonal Gammopathy Research Group to describe cases that would otherwise meet the criteria for MGUS, but demonstrate renal insufficiency and monoclonal immunoglobulin deposits in the kidney by immunofluorescence [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15290/abstract/58\">",
"     58",
"    </a>",
"    ]. Renal tissue deposition or precipitation of monoclonal immunoglobulin or its components has been associated with a variety of kidney diseases, including but not limited to AL amyloidosis, monoclonal immunoglobulin deposition disease, light chain proximal tubulopathy, and proliferative glomerulonephritis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/48/27400?source=see_link\">",
"     \"Types of renal disease in multiple myeloma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The presence of MGUS is not in itself an indication for renal biopsy and the introduction of this terminology does not change the indications for renal biopsy. However, this distinction between MGUS and MGRS is important because the monoclonal protein appears to be the direct cause of kidney disease in such cases and treatment that targets the responsible clone is associated with restoration and preservation of kidney function [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15290/abstract/58\">",
"     58",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/11/21690?source=see_link\">",
"     \"Indications for and complications of renal biopsy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/17/13594?source=see_link&amp;anchor=H56342434#H56342434\">",
"     \"Evaluation and treatment of membranoproliferative glomerulonephritis\", section on 'Treatment of the underlying cause'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H174977369\">",
"    <span class=\"h2\">",
"     Idiopathic Bence Jones proteinuria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Monoclonal light chains can be found in the urine (Bence Jones proteinuria) if their production exceeds the rate of light chain re-absorption in the kidneys (",
"    <a class=\"graphic graphic_figure graphicRef55073 \" href=\"UTD.htm?7/20/7503\">",
"     figure 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef75044 \" href=\"UTD.htm?42/51/43824\">",
"     figure 6",
"    </a>",
"    ). Bence Jones proteinuria is present in a subset of patients with multiple myeloma, amyloidosis, and Waldenstrom macroglobulinemia (WM). Previously, patients with free light chains in their urine and no other evidence of plasma cell or lymphoproliferative disorder were said to have idiopathic (or &ldquo;benign&rdquo;) Bence Jones proteinuria. Such patients represent patients with light chain MGUS (LC-MGUS) in whom the light chain levels were high enough to be excreted in sufficient quantities so as to enable detection on urine protein electrophoresis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15290/abstract/1\">",
"     1",
"    </a>",
"    ]. As such, idiopathic Bence Jones proteinuria is considered an intermediate stage of disease between LC-MGUS and light chain multiple myeloma (MM), much like smoldering MM is an intermediate stage between IgG MGUS and IgG MM.",
"   </p>",
"   <p>",
"    The presence of large amounts of monoclonal light chain in the urine (Bence Jones proteinuria &gt;1",
"    <span class=\"nowrap\">",
"     gram/24",
"    </span>",
"    hours) suggests a malignant process. However, smaller amounts of monoclonal light chains in the urine can be seen in MGUS and their presence does not distinguish MGUS from myeloma or a related malignancy. Many patients with MGUS excrete a small amount of monoclonal light chain in the urine but remain stable for many years.",
"   </p>",
"   <p>",
"    To make a diagnosis of idiopathic Bence Jones proteinuria, the following criteria must be met [",
"    <a class=\"abstract\" href=\"UTD.htm?14/59/15290/abstract/70\">",
"     70",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Monoclonal light chains in the urine (Bence Jones proteinuria)",
"     </li>",
"     <li>",
"      No immunoglobulin heavy chain expression in the serum or urine",
"     </li>",
"     <li>",
"      No lytic bone lesions, hypercalcemia, anemia, renal failure or other signs of MM, WM, or amyloidosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     AL amyloidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary (amyloid light chain) amyloidosis and light chain deposition disease are plasma cell proliferative disorders associated with the pathologic deposition of monoclonal light chains. In primary (AL) amyloidosis, there is deposition of linear non-branching fibrils that are derived from monoclonal immunoglobulin light chains. These fibrils can produce the nephrotic syndrome, heart failure, hepatomegaly, and other findings that are not seen in MGUS. In light chain deposition disease, there is deposition of intact monoclonal immunoglobulin light chains commonly in the kidney resulting in nephrotic syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/62/35815?source=see_link\">",
"     \"Pathogenesis of immunoglobulin light chain (AL) amyloidosis and light and heavy chain deposition diseases\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/15/7418?source=see_link\">",
"     \"Clinical presentation, laboratory manifestations, and diagnosis of immunoglobulin light chain (AL) amyloidosis (primary amyloidosis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As noted above, the diagnosis of MGUS requires the absence of anemia, hypercalcemia, renal failure, and lytic bone lesions related to the plasma cell proliferative disorder. However, the presence of renal failure in conjunction with an M protein does not automatically indicate AL amyloidosis, since these abnormalities may be totally unrelated (eg, MGUS in a patient with renal failure secondary to diabetic or hypertensive nephropathy).",
"   </p>",
"   <p>",
"    The diagnosis of primary (AL) amyloidosis is initially suspected from typical clinical findings (eg, macroglossia, nephrotic range proteinuria, restrictive cardiomyopathy, in conjunction with a serum or urinary monoclonal protein) and is confirmed by demonstrating the following two features:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The presence of amyloid deposition on biopsy of the abdominal fat pad, bone marrow, rectum, or, if necessary, the involved organ (eg, kidney, liver, sural nerve), PLUS:",
"     </li>",
"     <li>",
"      Evidence of a clonal plasma cell proliferative disorder",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11684707\">",
"    <span class=\"h1\">",
"     CLINICAL COURSE AND MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Each of the three distinct clinical types of MGUS has a small risk of progressing to a unique intermediate (more advanced) premalignant stage and to a malignant plasma cell dyscrasia or lymphoproliferative disorder. Patients with MGUS should be monitored for disease progression and for potential complications. This is presented in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/60/4041?source=see_link&amp;anchor=H3221500#H3221500\">",
"     \"Clinical course and management of monoclonal gammopathy of undetermined significance\", section on 'Monitoring for progression'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?16/23/16754?source=see_link\">",
"       \"Patient information: Monoclonal gammopathy of undetermined significance (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Monoclonal gammopathy of undetermined significance (MGUS) is an asymptomatic premalignant clonal plasma cell or lymphoplasmacytic proliferative disorder. MGUS occurs in over 3 percent of the general Caucasian population over the age of 50 and is typically detected as an incidental finding when patients undergo a protein electrophoresis as part of an evaluation for a wide variety of clinical symptoms and disorders.",
"     </li>",
"     <li>",
"      There are three distinct clinical types of MGUS, each with a risk of progressing through a unique intermediate (more advanced) premalignant stage and then to a malignant plasma cell dyscrasia or lymphoproliferative disorder (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/60/4041?source=see_link&amp;anchor=H22391006#H22391006\">",
"       \"Clinical course and management of monoclonal gammopathy of undetermined significance\", section on 'Disease progression'",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Non-IgM MGUS (IgG, IgA, or IgD MGUS) is the most common type of MGUS and has the potential to progress to smoldering (asymptomatic) multiple myeloma and to symptomatic multiple myeloma. Less frequently, these patients progress to AL amyloidosis, light chain deposition disease, or another lymphoproliferative disorder.",
"     </li>",
"     <li>",
"      IgM MGUS accounts for approximately 15 percent of MGUS cases. It is considered separately from the non-IgM MGUS because it has the potential to progress to smoldering Waldenstrom macroglobulinemia and then symptomatic Waldenstrom macroglobulinemia, lymphoma, or AL amyloidosis. Infrequently, IgM MGUS can progress to IgM multiple myeloma.",
"     </li>",
"     <li>",
"      Light chain MGUS (LC-MGUS) may progress to idiopathic Bence Jones proteinuria and to light chain multiple myeloma, AL amyloidosis, or light chain deposition disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The presence of MGUS is suspected in an asymptomatic patient in whom a serum monoclonal immunoglobulin has been detected in a concentration of &lt;3",
"      <span class=\"nowrap\">",
"       g/dL.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      At a minimum, patients suspected of having MGUS should be evaluated with the following studies (see",
"      <a class=\"local\" href=\"#H90175591\">",
"       'Evaluation'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Complete blood count",
"     </li>",
"     <li>",
"      Serum calcium and creatinine",
"     </li>",
"     <li>",
"      Serum protein electrophoresis and immunofixation",
"     </li>",
"     <li>",
"      Urine protein electrophoresis and immunofixation",
"     </li>",
"     <li>",
"      Serum free light chain assay",
"     </li>",
"     <li>",
"      Quantitation of immunoglobulins",
"     </li>",
"     <li>",
"      Metastatic bone survey in patients with intermediate or high-risk MGUS and in any patient where there is a concern for myeloma (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/60/4041?source=see_link&amp;anchor=H22391048#H22391048\">",
"       \"Clinical course and management of monoclonal gammopathy of undetermined significance\", section on 'Risk stratification'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The diagnosis of MGUS (non-IgM and IgM) is confirmed when the following three criteria have been met (",
"      <a class=\"graphic graphic_table graphicRef57627 \" href=\"UTD.htm?41/38/42603\">",
"       table 4",
"      </a>",
"      ) (see",
"      <a class=\"local\" href=\"#H90176110\">",
"       'Diagnostic criteria'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The presence of a serum monoclonal protein (M-protein, whether IgA, IgG, or IgM), at a concentration &lt;3",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"     </li>",
"     <li>",
"      Fewer than 10 percent plasma cells in the bone marrow",
"     </li>",
"     <li>",
"      The absence of lytic bone lesions, anemia, hypercalcemia, and renal insufficiency related to the plasma cell proliferative process",
"     </li>",
"     <li>",
"      Specifically, patients should not have leukocytosis, abnormal circulating cells, lymphadenopathy, hepatomegaly, splenomegaly, or undiagnosed mass lesions that can be attributed to a clonal plasma cell or lymphoproliferative disorder.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      MGUS must be differentiated from diseases that also present with a monoclonal gammopathy. These include multiple myeloma (smoldering or symptomatic), Waldenstrom macroglobulinemia (smoldering or symptomatic), idiopathic Bence Jones proteinuria, and primary amyloidosis (AL). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15290/abstract/1\">",
"      Rajkumar SV, Kyle RA, Buadi FK. Advances in the diagnosis, classification, risk stratification, and management of monoclonal gammopathy of undetermined significance: implications for recategorizing disease entities in the presence of evolving scientific evidence. Mayo Clin Proc 2010; 85:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15290/abstract/2\">",
"      Kyle RA, Rajkumar SV. Monoclonal gammopathy of undetermined significance. Br J Haematol 2006; 134:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15290/abstract/3\">",
"      Kyle RA, Rajkumar SV. Monoclonal gammopathy of undetermined significance and smouldering multiple myeloma: emphasis on risk factors for progression. Br J Haematol 2007; 139:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15290/abstract/4\">",
"      Bird J, Behrens J, Westin J, et al. UK Myeloma Forum (UKMF) and Nordic Myeloma Study Group (NMSG): guidelines for the investigation of newly detected M-proteins and the management of monoclonal gammopathy of undetermined significance (MGUS). Br J Haematol 2009; 147:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15290/abstract/5\">",
"      Kyle RA, Durie BG, Rajkumar SV, et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia 2010; 24:1121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15290/abstract/6\">",
"      Axelsson U. A 20-year follow-up study of 64 subjects with M-components. Acta Med Scand 1986; 219:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15290/abstract/7\">",
"      Kyle RA, Finkelstein S, Elveback LR, Kurland LT. Incidence of monoclonal proteins in a Minnesota community with a cluster of multiple myeloma. Blood 1972; 40:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15290/abstract/8\">",
"      Saleun JP, Vicariot M, Deroff P, Morin JF. Monoclonal gammopathies in the adult population of Finist&egrave;re, France. J Clin Pathol 1982; 35:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15290/abstract/9\">",
"      Neriishi K, Nakashima E, Suzuki G. Monoclonal gammopathy of undetermined significance in atomic bomb survivors: incidence and transformation to multiple myeloma. Br J Haematol 2003; 121:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15290/abstract/10\">",
"      Iwanaga M, Tagawa M, Tsukasaki K, et al. Prevalence of monoclonal gammopathy of undetermined significance: study of 52,802 persons in Nagasaki City, Japan. Mayo Clin Proc 2007; 82:1474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15290/abstract/11\">",
"      Kyle RA, Therneau TM, Rajkumar SV, et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med 2006; 354:1362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15290/abstract/12\">",
"      Smith A, Howell D, Patmore R, et al. Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network. Br J Cancer 2011; 105:1684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15290/abstract/13\">",
"      Crawford J, Eye MK, Cohen HJ. Evaluation of monoclonal gammopathies in the \"well\" elderly. Am J Med 1987; 82:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15290/abstract/14\">",
"      Therneau TM, Kyle RA, Melton LJ 3rd, et al. Incidence of monoclonal gammopathy of undetermined significance and estimation of duration before first clinical recognition. Mayo Clin Proc 2012; 87:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15290/abstract/15\">",
"      Singh J, Dudley AW Jr, Kulig KA. Increased incidence of monoclonal gammopathy of undetermined significance in blacks and its age-related differences with whites on the basis of a study of 397 men and one woman in a hospital setting. J Lab Clin Med 1990; 116:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15290/abstract/16\">",
"      Cohen HJ, Crawford J, Rao MK, et al. Racial differences in the prevalence of monoclonal gammopathy in a community-based sample of the elderly. Am J Med 1998; 104:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15290/abstract/17\">",
"      Landgren O, Gridley G, Turesson I, et al. Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States. Blood 2006; 107:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15290/abstract/18\">",
"      Landgren O, Katzmann JA, Hsing AW, et al. Prevalence of monoclonal gammopathy of undetermined significance among men in Ghana. Mayo Clin Proc 2007; 82:1468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15290/abstract/19\">",
"      Wadhera RK, Rajkumar SV. Prevalence of monoclonal gammopathy of undetermined significance: a systematic review. Mayo Clin Proc 2010; 85:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15290/abstract/20\">",
"      Dispenzieri A, Katzmann JA, Kyle RA, et al. Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study. Lancet 2010; 375:1721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15290/abstract/21\">",
"      Landgren O, Rajkumar SV, Pfeiffer RM, et al. Obesity is associated with an increased risk of monoclonal gammopathy of undetermined significance among black and white women. Blood 2010; 116:1056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15290/abstract/22\">",
"      Ruiz-Delgado GJ, G&oacute;mez Rangel JD. [Monoclonal gammopathy of undetermined significance (MGUS) in Mexican mestizos: one institution's experience]. Gac Med Mex 2004; 140:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15290/abstract/23\">",
"      Greenberg AJ, Rajkumar SV, Vachon CM. Familial monoclonal gammopathy of undetermined significance and multiple myeloma: epidemiology, risk factors, and biological characteristics. Blood 2012; 119:5359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15290/abstract/24\">",
"      Landgren O, Kristinsson SY, Goldin LR, et al. Risk of plasma cell and lymphoproliferative disorders among 14621 first-degree relatives of 4458 patients with monoclonal gammopathy of undetermined significance in Sweden. Blood 2009; 114:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15290/abstract/25\">",
"      Vachon CM, Kyle RA, Therneau TM, et al. Increased risk of monoclonal gammopathy in first-degree relatives of patients with multiple myeloma or monoclonal gammopathy of undetermined significance. Blood 2009; 114:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15290/abstract/26\">",
"      Greenberg AJ, Rajkumar SV, Larson DR, et al. Increased prevalence of light chain monoclonal gammopathy of undetermined significance (LC-MGUS) in first-degree relatives of individuals with multiple myeloma. Br J Haematol 2012; 157:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15290/abstract/27\">",
"      Vanderschueren S, Mylle M, Dierickx D, et al. Monoclonal gammopathy of undetermined significance: significant beyond hematology. Mayo Clin Proc 2009; 84:842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15290/abstract/28\">",
"      Rossi D, De Paoli L, Franceschetti S, et al. Prevalence and clinical characteristics of immune thrombocytopenic purpura in a cohort of monoclonal gammopathy of uncertain significance. Br J Haematol 2007; 138:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15290/abstract/29\">",
"      Lindqvist EK, Goldin LR, Landgren O, et al. Personal and family history of immune-related conditions increase the risk of plasma cell disorders: a population-based study. Blood 2011; 118:6284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15290/abstract/30\">",
"      Bida JP, Kyle RA, Therneau TM, et al. Disease associations with monoclonal gammopathy of undetermined significance: a population-based study of 17,398 patients. Mayo Clin Proc 2009; 84:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15290/abstract/31\">",
"      Melton LJ 3rd, Rajkumar SV, Khosla S, et al. Fracture risk in monoclonal gammopathy of undetermined significance. J Bone Miner Res 2004; 19:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15290/abstract/32\">",
"      Bazari H, Attar EC, Dahl DM, et al. Case records of the Massachusetts General Hospital. Case 23-2010. A 49-year-old man with erythrocytosis, perinephric fluid collections, and renal failure. N Engl J Med 2010; 363:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15290/abstract/33\">",
"      Sykes DB, Schroyens W, O'Connell C. The TEMPI syndrome--a novel multisystem disease. N Engl J Med 2011; 365:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15290/abstract/34\">",
"      Kwok M, Korde N, Landgren O. Bortezomib to treat the TEMPI syndrome. N Engl J Med 2012; 366:1843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15290/abstract/35\">",
"      Schroyens W, O'Connell C, Sykes DB. Complete and partial responses of the TEMPI syndrome to bortezomib. N Engl J Med 2012; 367:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15290/abstract/36\">",
"      Kyle RA, Therneau TM, Rajkumar SV, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 2002; 346:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15290/abstract/37\">",
"      Blade J, Lopez-Guillermo A, Rozman C, et al. Malignant transformation and life expectancy in monoclonal gammopathy of undetermined significance. Br J Haematol 1992; 81:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15290/abstract/38\">",
"      Kyle RA. \"Benign\" monoclonal gammopathy--after 20 to 35 years of follow-up. Mayo Clin Proc 1993; 68:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15290/abstract/39\">",
"      Kyle RA, Robinson RA, Katzmann JA. The clinical aspects of biclonal gammopathies. Review of 57 cases. Am J Med 1981; 71:999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15290/abstract/40\">",
"      Kumar S, Rajkumar SV, Kyle RA, et al. Prognostic value of circulating plasma cells in monoclonal gammopathy of undetermined significance. J Clin Oncol 2005; 23:5668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15290/abstract/41\">",
"      Witzig TE, Kyle RA, O'Fallon WM, Greipp PR. Detection of peripheral blood plasma cells as a predictor of disease course in patients with smouldering multiple myeloma. Br J Haematol 1994; 87:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15290/abstract/42\">",
"      Fonseca R, Bailey RJ, Ahmann GJ, et al. Genomic abnormalities in monoclonal gammopathy of undetermined significance. Blood 2002; 100:1417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15290/abstract/43\">",
"      Zandecki M, La&iuml; JL, Genevi&egrave;ve F, et al. Several cytogenetic subclones may be identified within plasma cells from patients with monoclonal gammopathy of undetermined significance, both at diagnosis and during the indolent course of this condition. Blood 1997; 90:3682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15290/abstract/44\">",
"      Rasillo A, Tabernero MD, S&aacute;nchez ML, et al. Fluorescence in situ hybridization analysis of aneuploidization patterns in monoclonal gammopathy of undetermined significance versus multiple myeloma and plasma cell leukemia. Cancer 2003; 97:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15290/abstract/45\">",
"      Brousseau M, Leleu X, Gerard J, et al. Hyperdiploidy is a common finding in monoclonal gammopathy of undetermined significance and monosomy 13 is restricted to these hyperdiploid patients. Clin Cancer Res 2007; 13:6026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15290/abstract/46\">",
"      Kuehl WM, Bergsagel PL. Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer 2002; 2:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15290/abstract/47\">",
"      Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med 2004; 351:1860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15290/abstract/48\">",
"      Chang H, Yeung J, Xu W, et al. Significant increase of CKS1B amplification from monoclonal gammopathy of undetermined significance to multiple myeloma and plasma cell leukaemia as demonstrated by interphase fluorescence in situ hybridisation. Br J Haematol 2006; 134:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15290/abstract/49\">",
"      Berenson JR, Anderson KC, Audell RA, et al. Monoclonal gammopathy of undetermined significance: a consensus statement. Br J Haematol 2010; 150:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15290/abstract/50\">",
"      Dimopoulos M, Terpos E, Comenzo RL, et al. International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma. Leukemia 2009; 23:1545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15290/abstract/51\">",
"      Kyle RA. Monoclonal gammopathy of undetermined significance. Natural history in 241 cases. Am J Med 1978; 64:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15290/abstract/52\">",
"      International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003; 121:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15290/abstract/53\">",
"      Kyle RA. The monoclonal gammopathies. Clin Chem 1994; 40:2154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15290/abstract/54\">",
"      Kyle RA, Therneau TM, Rajkumar SV, et al. Long-term follow-up of IgM monoclonal gammopathy of undetermined significance. Blood 2003; 102:3759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15290/abstract/55\">",
"      Mill&aacute; F, Oriol A, Aguilar J, et al. Usefulness and reproducibility of cytomorphologic evaluations to differentiate myeloma from monoclonal gammopathies of unknown significance. Am J Clin Pathol 2001; 115:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15290/abstract/56\">",
"      Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003; 78:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15290/abstract/57\">",
"      Bella&iuml;che L, Laredo JD, Liot&eacute; F, et al. Magnetic resonance appearance of monoclonal gammopathies of unknown significance and multiple myeloma. The GRI Study Group. Spine (Phila Pa 1976) 1997; 22:2551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15290/abstract/58\">",
"      Leung N, Bridoux F, Hutchison CA, et al. Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant. Blood 2012; 120:4292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15290/abstract/59\">",
"      Bataille R, Jourdan M, Zhang XG, Klein B. Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias. J Clin Invest 1989; 84:2008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15290/abstract/60\">",
"      Gonchoroff NJ, Greipp PR, Kyle RA, Katzmann JA. A monoclonal antibody reactive with 5-bromo-2-deoxyuridine that does not require DNA denaturation. Cytometry 1985; 6:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15290/abstract/61\">",
"      Roodman GD. Role of the bone marrow microenvironment in multiple myeloma. J Bone Miner Res 2002; 17:1921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15290/abstract/62\">",
"      Abe M, Hiura K, Wilde J, et al. Role for macrophage inflammatory protein (MIP)-1alpha and MIP-1beta in the development of osteolytic lesions in multiple myeloma. Blood 2002; 100:2195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15290/abstract/63\">",
"      Lacy MQ, Donovan KA, Heimbach JK, et al. Comparison of interleukin-1 beta expression by in situ hybridization in monoclonal gammopathy of undetermined significance and multiple myeloma. Blood 1999; 93:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15290/abstract/64\">",
"      Kyle RA, Greipp PR. Smoldering multiple myeloma. N Engl J Med 1980; 302:1347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15290/abstract/65\">",
"      Kyle RA, Remstein ED, Therneau TM, et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med 2007; 356:2582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15290/abstract/66\">",
"      Rajkumar SV, Larson D, Kyle RA. Diagnosis of smoldering multiple myeloma. N Engl J Med 2011; 365:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15290/abstract/67\">",
"      Wadhera RK, Kyle RA, Larson DR, et al. Incidence, clinical course, and prognosis of secondary monoclonal gammopathy of undetermined significance in patients with multiple myeloma. Blood 2011; 118:2985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15290/abstract/68\">",
"      Leleu X, Moreau AS, Weller E, et al. Serum immunoglobulin free light chain correlates with tumor burden markers in Waldenstrom macroglobulinemia. Leuk Lymphoma 2008; 49:1104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15290/abstract/69\">",
"      Owen RG, Treon SP, Al-Katib A, et al. Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 2003; 30:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/59/15290/abstract/70\">",
"      Kyle RA, Greipp PR. \"Idiopathic\" Bence Jones proteinuria: long-term follow-up in seven patients. N Engl J Med 1982; 306:564.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6652 Version 29.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-183.166.191.243-285D26EE14-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_59_15290=[""].join("\n");
var outline_f14_59_15290=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H39\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Family studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H90176672\">",
"      Associated conditions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H90177415\">",
"      PRESENTING FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H90177423\">",
"      Monoclonal proteins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H90179087\">",
"      Biclonal gammopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H90177451\">",
"      Laboratory artifacts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H90177465\">",
"      Peripheral smear",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H90177472\">",
"      Bone marrow examination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H282159971\">",
"      Screening",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H90175591\">",
"      Evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H90176110\">",
"      Diagnostic criteria",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H90176118\">",
"      - Non-IgM MGUS",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H174976281\">",
"      - IgM MGUS",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H90176125\">",
"      - Light-chain MGUS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H90179596\">",
"      - Smoldering multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H62135187\">",
"      - Secondary MGUS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H90179678\">",
"      Waldenstrom macroglobulinemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2549497\">",
"      Monoclonal gammopathy of renal significance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H174977369\">",
"      Idiopathic Bence Jones proteinuria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      AL amyloidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11684707\">",
"      CLINICAL COURSE AND MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/6652\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/6652|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?6/58/7087\" title=\"diagnostic image 1\">",
"      Immunoglobin pattern MM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/6652|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/3/21566\" title=\"figure 1\">",
"      Monoclonal pattern on SPEP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?29/1/29727\" title=\"figure 2\">",
"      Biclonal gammopathy on SPEP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/39/4735\" title=\"figure 3\">",
"      Monoclonal pattern immunofixation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/4/18510\" title=\"figure 4\">",
"      Polyclonal pattern on SPEP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?7/20/7503\" title=\"figure 5\">",
"      Bence Jones protein UPEP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/51/43824\" title=\"figure 6\">",
"      Bence Jones protein immunofix",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/6652|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/33/28183\" title=\"picture 1\">",
"      Rouleaux in myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/6652|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?43/21/44380\" title=\"table 1\">",
"      Causes monoclonal gammopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/17/14620\" title=\"table 2\">",
"      MGUS characteristics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/46/12014\" title=\"table 3\">",
"      Monoclonal gammopathies disease definitions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/38/42603\" title=\"table 4\">",
"      Diagnostic criteria for myeloma MGUS and SMM",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/12/26824?source=related_link\">",
"      Acquired C1 inhibitor deficiency: Clinical manifestations, epidemiology, pathogenesis, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/20/25927?source=related_link\">",
"      Acquired C1 inhibitor deficiency: Management and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/37/13914?source=related_link\">",
"      Assessment of urinary protein excretion and evaluation of isolated non-nephrotic proteinuria in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/60/4041?source=related_link\">",
"      Clinical course and management of monoclonal gammopathy of undetermined significance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/13/35034?source=related_link\">",
"      Clinical features, laboratory manifestations, and diagnosis of multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/61/38872?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of lymphoplasmacytic lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/15/7418?source=related_link\">",
"      Clinical presentation, laboratory manifestations, and diagnosis of immunoglobulin light chain (AL) amyloidosis (primary amyloidosis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/29/8666?source=related_link\">",
"      Determination of initial therapy in patients with multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/47/762?source=related_link\">",
"      Epidemiology, pathogenesis, clinical manifestations and diagnosis of Waldenstr&ouml;m macroglobulinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/17/13594?source=related_link\">",
"      Evaluation and treatment of membranoproliferative glomerulonephritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/26/38313?source=related_link\">",
"      Evaluation of the peripheral blood smear",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/11/21690?source=related_link\">",
"      Indications for and complications of renal biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/20/27977?source=related_link\">",
"      Pathobiology of multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/62/35815?source=related_link\">",
"      Pathogenesis of immunoglobulin light chain (AL) amyloidosis and light and heavy chain deposition diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?20/41/21151?source=related_link\">",
"      Patient information: Collection of a 24-hour urine specimen (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/23/16754?source=related_link\">",
"      Patient information: Monoclonal gammopathy of undetermined significance (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/58/10154?source=related_link\">",
"      Recognition of monoclonal proteins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/48/27400?source=related_link\">",
"      Types of renal disease in multiple myeloma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_59_15291="USPSTF evidence grade";
var content_f14_59_15291=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F73780&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F73780&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    USPSTF grading scheme for quality of evidence",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Good:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Evidence includes consistent results",
"from well-designed, well-conducted studies in representative",
"populations that directly assess effects on health outcomes.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Fair:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Evidence is sufficient to determine",
"effects on health outcomes, but the strength of the evidence is limited",
"by the number, quality, or consistency of the individual studies, generalizability to routine",
"practice, or indirect nature of the evidence on health outcomes.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Poor:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Evidence is insufficient to assess",
"the effects on health outcomes because of limited number or power of",
"studies, important flaws in their design or conduct, gaps in the chain of evidence, or lack of information on",
"important health outcomes.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    The USPSTF grades the quality of the overall evidence for a service on a 3-point scale (good, fair, poor).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From U.S. Preventive Services Task Force Ratings: Strength of Recommendations and Quality of Evidence. Guide to Clinical Preventive Services, Third Edition: Periodic Updates, 2000-2003. Agency for Healthcare Research and Quality, Rockville, MD. file://www.ahrq.gov/clinic/3rduspstf/ratings.htm.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_59_15291=[""].join("\n");
var outline_f14_59_15291=null;
var title_f14_59_15292="Lung cancer risk Hodgkin lymphoma";
var content_f14_59_15292=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F78440&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F78440&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Relative risk of developing lung cancer in Hodgkin lymphoma by treatment modality and smoking status",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Radiation",
"       </td>",
"       <td class=\"subtitle1\">",
"        Alkylating agent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Smoking",
"       </td>",
"       <td class=\"subtitle1\">",
"        Relative risk*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        1.0",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        4.3 (2 to 12)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        6.0 (2 to 20)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        7.2 (3 to 21)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        7.2 (3 to 22)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        16.8 (6 to 53)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        20.2 (7 to 68)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        49.1 (15 to 187)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     Radiation: radiation &ge;5 Gy to specific location in the lung where cancer was diagnosed. Smoking: estimated smoking habit&nbsp;five years before diagnosis date of lung cancer. Smokers include those smoking one or more packs of cigarettes per day. Those smoking less than this amount, former cigarette smokers, and smokers of pipes or cigars were considered to be non-smokers in this analysis.",
"     <br>",
"      * Relative risk of developing lung cancer is shown with 95 percent confidence interval in parentheses.",
"      <br>",
"       &bull; Reference group.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from:&nbsp;Travis LB, Gospodarowicz M, Curtis RE, et al. Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease. J Natl Cancer Inst 2002; 94:182.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_59_15292=[""].join("\n");
var outline_f14_59_15292=null;
var title_f14_59_15293="Pneumococcal vaccines";
var content_f14_59_15293=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F77274&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F77274&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Comparison of serotypes in pneumococcal vaccines",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"4\">",
"        Conjugate vaccines",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Polysaccharide vaccine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        PCV7",
"       </td>",
"       <td class=\"subtitle2\">",
"        PCV10*",
"       </td>",
"       <td class=\"subtitle2\">",
"        PCV13",
"       </td>",
"       <td class=\"subtitle2\">",
"        PCV15",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"2\">",
"        PPSV23",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6B",
"       </td>",
"       <td>",
"        6B",
"       </td>",
"       <td>",
"        6B",
"       </td>",
"       <td>",
"        6B",
"       </td>",
"       <td>",
"        6B",
"       </td>",
"       <td>",
"        8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        9V",
"       </td>",
"       <td>",
"        9V",
"       </td>",
"       <td>",
"        9V",
"       </td>",
"       <td>",
"        9V",
"       </td>",
"       <td>",
"        9V",
"       </td>",
"       <td>",
"        9N",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        14",
"       </td>",
"       <td>",
"        14",
"       </td>",
"       <td>",
"        14",
"       </td>",
"       <td>",
"        14",
"       </td>",
"       <td>",
"        14",
"       </td>",
"       <td>",
"        10A",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        18C",
"       </td>",
"       <td>",
"        18C",
"       </td>",
"       <td>",
"        18C",
"       </td>",
"       <td>",
"        18C",
"       </td>",
"       <td>",
"        18C",
"       </td>",
"       <td>",
"        11A",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        19F",
"       </td>",
"       <td>",
"        19F",
"       </td>",
"       <td>",
"        19F",
"       </td>",
"       <td>",
"        19F",
"       </td>",
"       <td>",
"        19F",
"       </td>",
"       <td>",
"        12F",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        23F",
"       </td>",
"       <td>",
"        23F",
"       </td>",
"       <td>",
"        23F",
"       </td>",
"       <td>",
"        23F",
"       </td>",
"       <td>",
"        23F",
"       </td>",
"       <td>",
"        15B",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        17F",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        20",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        22F",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        33F",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        7F",
"       </td>",
"       <td>",
"        7F",
"       </td>",
"       <td>",
"        7F",
"       </td>",
"       <td>",
"        7F",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        19A",
"       </td>",
"       <td>",
"        19A",
"       </td>",
"       <td>",
"        19A",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        6A",
"       </td>",
"       <td>",
"        6A",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        22F",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        33F",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     PCV7: 7-valent pneumococcal conjugate vaccine; PCV10: 10-valent pneumococcal conjugate vaccine; PCV13: 13-valent pneumococcal conjugate vaccine; PCV15: 15-valent pneumococcal conjugate vaccine; PPSV23: 23-valent pneumococcal polysaccharide vaccine.",
"     <br>",
"      * Not available in the United States.",
"      <br>",
"       &bull; In development.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_59_15293=[""].join("\n");
var outline_f14_59_15293=null;
var title_f14_59_15294="Pain stages SCD";
var content_f14_59_15294=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F73221&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F73221&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 526px\">",
"   <div class=\"ttl\">",
"    The stages of pain in sickle cell disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 506px; height: 381px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Ballas, SK. The sickle cell painful crisis in adults: phases and objective signs. Hemoglobin 1995; 19:323.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_59_15294=[""].join("\n");
var outline_f14_59_15294=null;
var title_f14_59_15295="Scaphoid fx dislocation xray";
var content_f14_59_15295=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F74559&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F74559&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Adult scaphoid fracture-dislocation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 288px; height: 426px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This lateral radiograph of the wrist reveals a trans-scaphoid fracture dislocation. the white line shows lunate fossa, black outlines the capitate base. This clearly depicts the trans-scaphoid fracture-dislocation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kevin E Burroughs, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_59_15295=[""].join("\n");
var outline_f14_59_15295=null;
